Skip to content
Esta página está disponible en españolCambiar →

SEC filings · updated every 10 minutes

At the SEC on Monday, November 9

Monday, November 9, 2026 · 328 filings · latest: 21:55 ET

From the companies the site's managers follow: those held by 300+ 13F filers, or 30+ with concentrated managers or well-known investors. Form 144 notices from $1M and insider purchases from $100,000.

Companies with the most concentrated managers that filed that day

Filings of the day

328 filings from 287 companies

  • Klaviyo

    KVYO3 filings
    • 21:55 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Summit Partners Co-Invest (Kiwi) may sell up to 182,210 shares (~$3.8 million, 0.14% of shares outstanding) on or about November 9, 2026.

    • 21:55 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Summit Partners Growth Equity Fund IX-B may sell up to 1,712,242 shares (~$35.6 million, 1.32% of shares outstanding) on or about November 9, 2026.

    • 21:54 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Summit Partners Growth Equity Fund IX-A may sell up to 2,742,281 shares (~$57.1 million, 2.11% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 7 concentrated managers (+2 this quarter)
    • 278 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Werewolf Therapeutics

    HOWL2 filings
    • 21:49 ETMergers and tender offersSEC 425

      Communication about a merger or acquisition

    • 09:22 ETOtherSEC 8-K 7.01

      Regulation FD disclosure

      Company headline: “Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting”

      From the company's release
      Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting – In a Phase 1/1b clinical trial, WTX-124 was administered safely at its recommended Phase 2 dose of 18 mg IV Q2W in the outpatient setting as monotherapy and in combination with pembrolizumab…

    On GestorLens

    • 3 concentrated managers
    • 45 13F filers
    • 2 13D filings in the last year
    GestorLens profile
  • News

    NWSA2 filings
    • 21:38 ETOtherSEC 8-K 8.01

      Other events

      From the company's release
      Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
    • 07:02 ETOtherSEC 8-K 8.01

      Other events

      From the company's release
      Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

    On GestorLens

    • 8 concentrated managers
    • 636 13F filers

    Well-known investors: Starboard Value

    GestorLens profile
  • Duke Energy

    DUK
    • 21:18 ETDeals and acquisitionsSEC 8-K 1.01

      Entry into a material agreement

      From the filing
      On November 9, 2026, Duke Energy Corporation (the “Corporation”), Duke Energy Carolinas, LLC (“Duke Energy Carolinas”), Duke Energy Florida, LLC, Duke Energy Indiana, LLC, Duke Energy Kentucky, Inc., Duke Energy Ohio, Inc., Duke Energy Progress, LLC (“Duke Energy Progress”), and Piedmont Natural Gas Company, Inc.…

    On GestorLens

    • 22 concentrated managers
    • 2,495 13F filers
    GestorLens profile
  • AerCap Holdings

    AER
    • 21:06 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Peter Juhas may sell up to 20,000 shares (~$3.4 million) on or about November 10, 2026.

    On GestorLens

    • 19 concentrated managers (-2 this quarter)
    • 696 13F filers
    GestorLens profile
  • Knowles

    KN
    • 20:49 ET5%+ stakesSEC Schedule 13G/A

      Change in a passive 5%+ stake

      Goldman Sachs Asset Management reports 5% (4,247,177 shares), 5% or less as of September 30, 2026.

      Filed by: GOLDMAN SACHS ASSET MANAGEMENT, L.P.

    On GestorLens

    • 345 13F filers
    GestorLens profile
  • Tandem Diabetes Care

    TNDM
    • 20:40 ET5%+ stakesSEC Schedule 13G

      New passive 5%+ stake

      the Goldman Sachs Group and 1 related filer reported a stake: 5.9% (4,091,935 shares) (passive, 13G) as of September 30, 2026.

      Filed by: GOLDMAN SACHS GROUP INC

    On GestorLens

    • 6 concentrated managers
    • 275 13F filers
    GestorLens profile
  • Citi Trends

    CTRN
    • 20:30 ET5%+ stakesSEC Schedule 13D/A

      Change in a 5%+ stake with activist intent

      Fund 1 Investments updated its stake: 12.9% (1,073,486 shares) (active, 13D) as of November 5, 2026.

      Filed by: Fund 1 Investments, LLC

      From the filing
      Item 4 is hereby amended to add the following: The sales of Shares reported herein were undertaken as part of a portfolio rebalancing. The Reporting Person continues to express confidence in the Issuer's leadership and strategic direction, and its long-term value.

    On GestorLens

    • 3 concentrated managers (-1 this quarter)
    • 147 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Pacific Biosciences of California

    PACB
    • 20:24 ET5%+ stakesSEC Schedule 13G

      New passive 5%+ stake

      the Goldman Sachs Group and 1 related filer reported a stake: 7.6% (23,515,936 shares) (passive, 13G) as of September 30, 2026.

      Filed by: GOLDMAN SACHS GROUP INC

    On GestorLens

    • 4 concentrated managers (+1 this quarter)
    • 220 13F filers
    GestorLens profile
  • EPAM Systems

    EPAM
    • 20:21 ETDeals and acquisitionsSEC 8-K 1.01

      Entry into a material agreement

      From the filing
      On November 9, 2026, EPAM Systems, Inc. (the “Company”) entered into a Fixed Dollar Accelerated Share Repurchase Transaction agreement (the “ASR Agreement”) with UBS AG, London Branch, represented by UBS Securities LLC (“UBS”) to repurchase an aggregate of $500 million of shares of the Company’s common stock (the “Common Stock”).

    On GestorLens

    • 7 concentrated managers (+4 this quarter)
    • 444 13F filers
    GestorLens profile
  • Netstreit

    NTST
    • 20:16 ET5%+ stakesSEC Schedule 13G/A

      Change in a passive 5%+ stake

      the Goldman Sachs Group and 1 related filer report a 4.3% stake (4,405,517 shares), below 5% as of September 30, 2026.

      Filed by: GOLDMAN SACHS GROUP INC

    On GestorLens

    • 5 concentrated managers (+1 this quarter)
    • 269 13F filers
    • 2 insiders bought in 180 days ($120,094)
    GestorLens profile
  • People

    PPLI
    • 19:59 ET5%+ stakesSEC Schedule 13G/A

      Change in a passive 5%+ stake

      the Goldman Sachs Group and 1 related filer report a 3.7% stake (2,513,498 shares), below 5% as of September 30, 2026.

      Filed by: GOLDMAN SACHS GROUP INC

    On GestorLens

    • 10 concentrated managers (-1 this quarter)
    • 341 13F filers
    • 2 13D filings in the last year
    GestorLens profile
  • MetLife

    MET
    • 19:16 ETDeals and acquisitionsSEC 8-K 1.01

      Entry into a material agreement

      Also: New direct financial obligation

      From the filing
      On November 9, 2026, MetLife, Inc., a Delaware corporation (the “Company”), and MetLife Funding, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (together with the Company, the “Borrowers”), amended and restated in its entirety their Amended and Restated Credit Agreement, dated as of May 8, 2023 (as amended and restated, the “Amended and Restated Credit Agreement”), among the Borrowers…

    On GestorLens

    • 6 concentrated managers (+1 this quarter)
    • 1,452 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Exelixis

    EXEL2 filings
    • 19:13 ET5%+ stakesSEC Schedule 13G

      New passive 5%+ stake

      Farallon Capital Management and 15 related filers reported a stake: 6% (14,694,910 shares) (passive, 13G) as of November 9, 2026.

      Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

    • 19:10 ET5%+ stakesSEC Schedule 13D/A

      Change in a 5%+ stake with activist intent

      Farallon Capital Management and 15 related filers report a 4.9% stake (12,017,906 shares), below 5% as of November 6, 2026.

      Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

    On GestorLens

    • 6 concentrated managers
    • 761 13F filers
    • 2 13D filings in the last year
    GestorLens profile
  • FATE Therapeutics

    FATE
    • 19:08 ET5%+ stakesSEC Schedule 13D/A

      Change in a 5%+ stake with activist intent

      Redmile Group and 3 related filers updated their stake: 14.99% (19,164,572 shares) (active, 13D) as of November 5, 2026.

      Filed by: Redmile Group, LLC

    On GestorLens

    • 5 concentrated managers (-1 this quarter)
    • 157 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Sezzle

    SEZL
    • 18:43 ETOtherSEC 8-K 7.01

      Regulation FD disclosure

      From the company's release
      Launch of Premium Subscription Launch of Credit Reporting 1st Quarter of Profitability Initiatives Announced in Mar ‘22 Sep 2022 Jun 2023 Nasdaq Listing 4 Launch of Anywhere Subscription Aug 2023 Sep 2024 Mar 2025 Jun 2026 Oct 2026 Launch of WebBank Partnership & On - Demand Announced 6 - for - 1 Stock Split Launch of SezzleCash 5 Launch of Canada Anywhere Subscription Jul 2019 Australian Stock Exchange IPO Aug 2017…

    On GestorLens

    • 324 13F filers
    • 2 insiders bought in 180 days ($43,966)
    • 1 13D filings in the last year
    GestorLens profile
  • Tapestry

    TPR3 filings
    • 18:38 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Leonard Todd Kahn (officer) may sell up to 30,000 shares (~$4.1 million) on or about November 9, 2026.

    • 12:25 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: David E Howard (officer) may sell up to 55,323 shares (~$7.4 million) on or about November 9, 2026.

    • 11:42 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Denise Kulikowsky (officer) may sell up to 16,259 shares (~$2.2 million) on or about November 9, 2026.

    On GestorLens

    • 9 concentrated managers (+3 this quarter)
    • 1,105 13F filers
    GestorLens profile
  • L3harris Technologies

    LHX
    • 18:38 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Christopher Kubasik (officer) may sell up to 15,000 shares (~$4.1 million) on or about November 9, 2026.

    On GestorLens

    • 20 concentrated managers (-4 this quarter)
    • 1,698 13F filers
    GestorLens profile
  • Arxis

    ARXS
    • 18:38 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Kevin Perhamus (officer) may sell up to 25,000 shares (~$1.3 million) on or about November 9, 2026.

    On GestorLens

    • 3 concentrated managers (+3 this quarter)
    • 140 13F filers

    Well-known investors: Soros Fund

    GestorLens profile
  • Sirius XM Holdings

    SIRI2 filings
    • 18:12 ET5%+ stakesSEC Schedule 13D/A

      Change in a 5%+ stake with activist intent

      John C. Malone reports a 4.8% stake (16,127,021 shares), below 5% as of November 6, 2026.

      Filed by: MALONE JOHN C

    • 08:00 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      Company headline: “SiriusXM Announces CEO Transition”

      From the filing
      On November 9, 2026, Sirius XM Holdings Inc. (the “Company”) announced the appointment of Anjali Sud to serve as its Chief Executive Officer, effective as of January 1, 2027 (the “Start Date”).

    On GestorLens

    • 10 concentrated managers (+1 this quarter)
    • 601 13F filers
    • 1 13D filings in the last year

    Well-known investors: Berkshire Hathaway

    GestorLens profile
  • Loews

    L
    • 18:07 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: James S Tisch (director) may sell up to 254,600 shares (~$27.9 million, 0.13% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 8 concentrated managers
    • 788 13F filers
    • 1 insider bought in 180 days ($523,700)
    • 2 13D filings in the last year
    GestorLens profile
  • Rockwell Automation

    ROK
    • 17:48 ETInsider buyingSEC Form 4 (P)

      Open-market purchase by an insider

      Blake D. Moret (President and CEO) bought 4,000 shares for $1.5 million (avg. $386.36).

    On GestorLens

    • 12 concentrated managers (+2 this quarter)
    • 1,548 13F filers

    Well-known investors: Markel Group

    GestorLens profile
  • Equinox Gold

    EQX2 filings
    • 17:46 ETEarningsSEC 6-K

      Foreign issuer report

      Company announcement.

      Company headline: “Equinox Gold Reports Q3 Results; Transformational Combination Begins to Deliver”

      From the company's release
      Equinox Gold Corp. (TSX: EQX, NYSE American: EQX) (“Equinox Gold” or the “Company”) is pleased to announce its financial and operating results for the third quarter of 2026 (“Q3 2026”).
    • 17:45 ETDividends and buybacksSEC 6-K

      Foreign issuer report

      Company announcement.

      Company headline: “Equinox Gold Declares Quarterly Dividend”

      From the company's release
      Equinox Gold Corp. (TSX: EQX, NYSE American: EQX) (“Equinox Gold” or the “Company”) is pleased to announce that its Board of Directors (“Board”) has declared a dividend of US$0.0225 per common share for the third quarter of 2026.

    On GestorLens

    • 14 concentrated managers (+1 this quarter)
    • 327 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Block

    XYZ
    • 17:46 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Anthony M Eisen (director) may sell up to 100,000 shares (~$8.9 million) on or about November 9, 2026.

    On GestorLens

    • 15 concentrated managers
    • 1,086 13F filers

    Well-known investors: Dan Loeb, Tiger Global

    GestorLens profile
  • Willscot Holdings

    WSC

    On GestorLens

    • 5 concentrated managers (-1 this quarter)
    • 370 13F filers

    Well-known investors: Markel Group

    GestorLens profile
  • Arthur J. Gallagher

    AJG
    • 17:44 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Susan E Pietrucha (officer) may sell up to 15,020 shares (~$4.2 million) on or about November 9, 2026.

    On GestorLens

    • 21 concentrated managers (+4 this quarter)
    • 1,292 13F filers
    GestorLens profile
  • Synchrony Financial

    SYF
    • 17:42 ETOtherSEC 8-K 7.01

      Regulation FD disclosure

      From the company's release
      The following table provides monthly charge-off and delinquency statistics as of and for each of the thirteen months ended October 31, 2026.

    On GestorLens

    • 8 concentrated managers (+1 this quarter)
    • 1,012 13F filers

    Well-known investors: Semper Augustus

    GestorLens profile
  • Lantheus Holdings

    LNTH
    • 17:40 ETOtherSEC 8-K 8.01

      Other events

      From the filing
      On November 8, 2026, Lantheus Holdings, Inc., a Delaware corporation (“Lantheus” or the “Company”), entered into a definitive agreement with PharmaLogic Holdings Corp. (“PharmaLogic”) to sell its contract development and manufacturing organization (“CDMO”) business and Springfield, New Jersey manufacturing facility to PharmaLogic.

    On GestorLens

    • 9 concentrated managers (-1 this quarter)
    • 468 13F filers
    GestorLens profile
  • Stride

    LRN
    • 17:38 ETInsider buyingSEC Form 4 (P)

      Open-market purchase by an insider

      Dylan G. Haggart (director) bought 108,273 shares for $8.1 million (avg. $74.83).

    On GestorLens

    • 11 concentrated managers (-2 this quarter)
    • 413 13F filers
    • 2 insiders bought in 180 days ($31.5M)
    GestorLens profile
  • Micron Technology

    MU
    • 17:34 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Sumit Sadana (officer) may sell up to 5,000 shares (~$3.7 million) on or about November 9, 2026.

    On GestorLens

    • 75 concentrated managers (+21 this quarter)
    • 3,923 13F filers

    Well-known investors: David Tepper, Coatue, Soros Fund

    GestorLens profile
  • Climb Bio

    CLYM
    • 17:32 ET5%+ stakesSEC Schedule 13D/A

      Change in a 5%+ stake with activist intent

      RA Capital Management and 4 related filers updated their stake: 33% (23,941,277 shares) (active, 13D) as of November 5, 2026.

      Filed by: RA CAPITAL MANAGEMENT, L.P.

    On GestorLens

    • 4 concentrated managers (-1 this quarter)
    • 108 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Immunocore Holdings

    IMCR
    • 17:29 ET5%+ stakesSEC Schedule 13G

      New passive 5%+ stake

      Point72 Asset Management and 2 related filers reported a stake: 5.2% (2,720,043 shares) (passive, 13G) as of November 6, 2026.

      Filed by: Point72 Asset Management, L.P.

    On GestorLens

    • 9 concentrated managers (-1 this quarter)
    • 135 13F filers
    GestorLens profile
  • Mueller Water Products

    MWA
    • 17:22 ETOtherSEC 8-K 7.01

      Regulation FD disclosure

      Company headline: “Where Intelligence Meets Infrastructure® Investor Presentation November 11, 2026”

    On GestorLens

    • 2 concentrated managers (+1 this quarter)
    • 427 13F filers
    • 1 insider bought in 180 days ($89,917)
    GestorLens profile
  • Addus HomeCare

    ADUS
    • 17:21 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Dirk Allison (officer, director) may sell up to 98,958 shares (~$12.2 million, 0.53% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 1 concentrated managers (-1 this quarter)
    • 303 13F filers
    GestorLens profile
  • Globalfoundries

    GFS
    • 17:21 ETInsider buyingSEC Form 4 (P)

      Open-market purchase by an insider

      Jack R Lazar (director) bought 10,000 shares for $380,000 (avg. $38.00).

    On GestorLens

    • 4 concentrated managers (+3 this quarter)
    • 444 13F filers
    • 1 insider bought in 180 days ($93,688)
    GestorLens profile
  • Maplebear

    CART
    • 17:16 ETMergers and tender offersSEC 425

      Communication about a merger or acquisition

      Maplebear filed a communication about its merger.

      From the filing
      The following communications are being filed in connection with the acquisition of Maplebear Inc. (“Instacart” or the “Company”) by DoorDash, Inc. (“DoorDash”)

    On GestorLens

    • 15 concentrated managers (-1 this quarter)
    • 501 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Motorola Solutions

    MSI3 filings
    • 17:13 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Gregory Q Brown (officer, director) may sell up to 40,000 shares (~$21 million) on or about November 9, 2026.

    • 17:10 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: James Niewiara (officer) may sell up to 2,086 shares (~$1.1 million) on or about November 9, 2026.

    • 16:18 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Cynthia Yazdi (officer) may sell up to 4,229 shares (~$2.2 million) on or about November 9, 2026.

    On GestorLens

    • 18 concentrated managers (+2 this quarter)
    • 1,470 13F filers
    GestorLens profile
  • Vista Gold

    VGZ
    • 17:10 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

    On GestorLens

    • 1 concentrated managers
    • 97 13F filers

    Well-known investors: Markel Group

    GestorLens profile
  • Archer-Daniels-Midland

    ADM
    • 17:05 ETInsider buyingSEC Form 4 (P)

      Open-market purchase by an insider

      David R McAtee II (director) bought 2,800 shares for $196,756 (avg. $70.27).

    On GestorLens

    • 3 concentrated managers
    • 1,167 13F filers

    Well-known investors: Markel Group, Soros Fund

    GestorLens profile
  • Hallador Energy

    HNRG
    • 17:05 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

    On GestorLens

    • 6 concentrated managers (+1 this quarter)
    • 173 13F filers
    • 3 insiders bought in 180 days ($674,845)
    • 1 13D filings in the last year
    GestorLens profile
  • WESCO International

    WCC
    • 17:02 ETInsider buyingSEC Form 4 (P)

      Open-market purchase by an insider

      Indraneel Dev (EVP & CFO) bought 1,725 shares for $503,527 (avg. $291.90).

    On GestorLens

    • 10 concentrated managers
    • 708 13F filers
    • 1 insider bought in 180 days ($351,254)

    Well-known investors: Seth Klarman

    GestorLens profile
  • Metropolitan Bank Holding

    MCB

    On GestorLens

    • 201 13F filers
    • 1 insider bought in 180 days ($89,980)
    • 1 13D filings in the last year

    Well-known investors: Soros Fund

    GestorLens profile
  • DoubleVerify Holdings

    DV

    On GestorLens

    • 3 concentrated managers (-1 this quarter)
    • 319 13F filers
    GestorLens profile
  • UWM Holdings

    UWMC

    On GestorLens

    • 3 concentrated managers (+2 this quarter)
    • 291 13F filers
    • 1 13D filings in the last year

    Well-known investors: Stanley Druckenmiller

    GestorLens profile
  • EquipmentShare.com

    EQPT
    • 16:57 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

    On GestorLens

    • 5 concentrated managers (+1 this quarter)
    • 145 13F filers
    • 4 insiders bought in 180 days ($4.6M)
    • 1 13D filings in the last year

    Well-known investors: Tiger Global

    GestorLens profile
  • Tidewater

    TDW
    • 16:55 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Company headline: “Tidewater Reports Results for the Nine Months Ended September 30, 2026”

      From the company's release
      Tidewater Inc. (NYSE:TDW) announced today revenue for the three and nine months ended September 30, 2026 of $360.4 million and $1,028.9 million, respectively, compared with $341.1 million and $1,016.0 million for the three and nine months ended September 30, 2025.

    On GestorLens

    • 14 concentrated managers
    • 361 13F filers
    GestorLens profile
  • Lumentum Holdings

    LITE
    • 16:55 ETMergers and tender offersSEC 425

      Communication about a merger or acquisition

      Lumentum Holdings filed a communication about its merger.

      From the filing
      The following communications were made available externally via social media by Lumentum Holdings Inc. (“Lumentum”) on November 9, 2026 in relation to an interview with Michael Hurlston, Chief Executive Officer of Lumentum, on November 6, 2026.

    On GestorLens

    • 33 concentrated managers (+2 this quarter)
    • 1,322 13F filers
    GestorLens profile
  • Nlight

    LASR
    • 16:53 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Scott H Keeney (officer, director) may sell up to 200,000 shares (~$8.4 million, 0.34% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 3 concentrated managers
    • 361 13F filers
    GestorLens profile
  • JBS

    JBS2 filings
    • 16:52 ETOtherSEC 8-K 3.02

      Unregistered sale of equity

      Unregistered sale of equity securities.

      Company headline: “JBS Enters Personal Care Market with Flora Acquisition”

      Also: Regulation FD disclosure; Other events

      From the filing
      The Class A Shares (as defined below), including the Class A Shares underlying the BDRs (as defined below), will be issued in reliance on the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), provided by Section 4(a)(2) thereof for transactions by an issuer not involving any public offering.
    • 16:30 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: revenue of $22.7 billion; EPS of $0.15 (adjusted: $0.16).

      Company headline: “JBS REPORTS THIRD QUARTER 2026 RESULTS”

      From the company's release
      Net Sales of $22.7 billion, up 1% from prior year

    On GestorLens

    • 3 concentrated managers
    • 268 13F filers

    Well-known investors: Stanley Druckenmiller

    GestorLens profile
  • Novanta

    NOVT
    • 16:50 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: revenue of $305 million; EPS of $0.05 (adjusted: $1.05).

      Company headline: “Novanta Announces Financial Results for the Third Quarter 2026”

      From the company's release
      Third Quarter 2026 GAAP Revenue increased 23% to $305 million

    On GestorLens

    • 2 concentrated managers (-1 this quarter)
    • 393 13F filers
    GestorLens profile
  • Lamar Advertising

    LAMR
    • 16:49 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Jay LeCoryelle Johnson may sell up to 7,600 shares (~$1.2 million) on or about November 9, 2026.

    On GestorLens

    • 12 concentrated managers (-1 this quarter)
    • 782 13F filers

    Well-known investors: Markel Group

    GestorLens profile
  • American Tower

    AMT
    • 16:49 ETOtherSEC 8-K 8.01

      Other events

      Company headline: “AMERICAN TOWER CORPORATION PRICES SENIOR NOTES OFFERING”

      From the company's release
      American Tower Corporation (NYSE: AMT) today announced the pricing of its registered public offering of senior unsecured notes due 2031, 2033 and 2036 in aggregate principal amounts of $450.0 million, $500.0 million and $550.0 million, respectively.

    On GestorLens

    • 31 concentrated managers
    • 1,764 13F filers
    • 1 insider bought in 180 days ($500,733)

    Well-known investors: Akre Capital

    GestorLens profile
  • AST Spacemobile

    ASTS
    • 16:49 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Company headline: “AST SpaceMobile Provides Business Update and Third Quarter 2026 Results”

      Also: Regulation FD disclosure

      From the company's release
      Nationwide intermittent service activation in the United States and other key markets before year-end 2026 Announced Blacklift, AST SpaceMobile’s own 20-ton reusable rocket to deploy BlueBird satellites into low Earth orbit, starting in late 2028 using Miranda and Vira engines Secured United States priority DPAS rating for dual-use government and commercial satellite program, with planned launches from SpaceX…

    On GestorLens

    • 4 concentrated managers (+1 this quarter)
    • 757 13F filers
    • 1 insider bought in 180 days ($619,200)
    • 4 13D filings in the last year
    GestorLens profile
  • Bally’s

    BALY
    • 16:48 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Company headline: “BALLY’S CORPORATION REPORTS PRELIMINARY THIRD QUARTER 2026 RESULTS WITH CONSOLIDATED REVENUE RISING 21.7% to $807.6 MILLION”

    On GestorLens

    • 3 concentrated managers
    • 64 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Energy Fuels

    UUUU
    • 16:48 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      From the filing
      On November 3, 2026, the board of directors (the "Board") of Energy Fuels Inc. (the "Company") appointed Mr. Jeffrey Olsen as (i) a director of the Company and (ii) a member of the Audit Committee of the Board, both with immediate effect.

    On GestorLens

    • 2 concentrated managers (-1 this quarter)
    • 352 13F filers
    • 2 insiders bought in 180 days ($1M)
    GestorLens profile
  • Liberty Media

    FWONK
    • 16:45 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Charles Carey (director) may sell up to 300,000 shares (~$30.9 million, 0.13% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 26 concentrated managers (+1 this quarter)
    • 630 13F filers
    • 1 13D filings in the last year

    Well-known investors: Tiger Global

    GestorLens profile
  • Allegiant Travel

    ALGT
    • 16:43 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Jude Bricker may sell up to 90,090 shares (~$8.8 million, 0.33% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 3 concentrated managers
    • 301 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • QXO

    QXO2 filings
    • 16:42 ETOtherSEC 8-K 7.01

      Regulation FD disclosure

      Company headline: “Transcript: Brad Jacobs Conference Call”

      From the company's release
      Over my career, I’ve founded and led eight billion-dollar or multibillion-dollar businesses, including six public companies. I love building multibillion-dollar market leaders, and I’m excited to have the opportunity to do it again.
    • 06:02 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Company headline: “QXO Announces Third Quarter 2026 Preliminary Financial Information”

      From the company's release
      QXO is a leading distributor and installer of building products serving an $800 billion market. The Company’s mission is to modernize the building products industry through advanced technology and a best-in-class customer experience.

    On GestorLens

    • 19 concentrated managers
    • 648 13F filers
    • 1 13D filings in the last year

    Well-known investors: Soros Fund

    GestorLens profile
  • Nike

    NKE
    • 16:42 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      From the filing
      On November 9, 2026, NIKE, Inc. (the “Company”) announced the appointment of Dan McKenzie as Vice President, Chief Accounting Officer, Finance Operations & Transformation, and the Company’s principal accounting officer, effective as of November 9, 2026 (the “Effective Date”).

    On GestorLens

    • 28 concentrated managers (-8 this quarter)
    • 1,737 13F filers

    Well-known investors: Markel Group

    GestorLens profile
  • APi Group

    APG
    • 16:39 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: James E. Lillie (director) may sell up to 375,000 shares (~$15.3 million, 0.09% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 13 concentrated managers (-2 this quarter)
    • 583 13F filers
    • 1 13D filings in the last year

    Well-known investors: Dan Loeb

    GestorLens profile
  • Procore Technologies

    PCOR
    • 16:38 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: William F Fleming (officer) may sell up to 16,852 shares (~$1.3 million) on or about November 9, 2026.

    On GestorLens

    • 10 concentrated managers (-3 this quarter)
    • 405 13F filers
    GestorLens profile
  • Compass

    COMP
    • 16:37 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Charles Phillips (director) may sell up to 366,282 shares (~$4.0 million, 0.05% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 15 concentrated managers (-1 this quarter)
    • 436 13F filers
    GestorLens profile
  • IQVIA Holdings

    IQV
    • 16:37 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Eric Sherbet (officer) may sell up to 4,446 shares (~$1.2 million) on or about November 9, 2026.

    On GestorLens

    • 19 concentrated managers
    • 1,090 13F filers

    Well-known investors: Markel Group

    GestorLens profile
  • Warby Parker

    WRBY2 filings
    • 16:37 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: David Gilboa (director, officer) may sell up to 75,402 shares (~$1.9 million, 0.07% of shares outstanding) on or about November 9, 2026.

    • 16:30 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Neil Blumenthal (director, officer) may sell up to 73,133 shares (~$1.9 million, 0.07% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 8 concentrated managers (+3 this quarter)
    • 304 13F filers
    GestorLens profile
  • First Horizon

    FHN2 filings
    • 16:36 ETPlanned insider salesSEC Form 144/A

      Amended notice of proposed sale (Form 144)

      Notice of proposed sale: D Bryan Jordan (officer, director) may sell up to 100,932 shares (~$2.4 million) on or about November 9, 2026.

    • 12:36 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: D Bryan Jordan (officer, director) may sell up to 100,932 shares (~$2.4 million) on or about November 9, 2026.

    On GestorLens

    • 8 concentrated managers
    • 676 13F filers
    GestorLens profile
  • Dianthus Therapeutics

    DNTH
    • 16:36 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Ryan Savitz (officer) may sell up to 124,042 shares (~$10.7 million, 0.22% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 21 concentrated managers (-3 this quarter)
    • 267 13F filers
    • 2 13D filings in the last year
    GestorLens profile
  • Amylyx Pharmaceuticals

    AMLX3 filings
    • 16:36 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Joshua Barry Cohen (director, officer) may sell up to 100,000 shares (~$3.0 million, 0.08% of shares outstanding) on or about November 9, 2026.

    • 16:36 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: James M Frates (officer) may sell up to 40,000 shares (~$1.2 million) on or about November 9, 2026.

    • 16:36 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Justin Klee (director, officer) may sell up to 100,000 shares (~$3.0 million, 0.08% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 9 concentrated managers
    • 206 13F filers
    • 1 insider bought in 180 days ($51,338)
    GestorLens profile
  • Neptune Insurance Holdings

    NP
    • 16:35 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Matthew Duffy (officer, director) may sell up to 88,000 shares (~$2.5 million, 0.09% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 4 concentrated managers
    • 136 13F filers

    Well-known investors: Soros Fund

    GestorLens profile
  • MACOM Technology Solutions Holdings

    MTSI
    • 16:34 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Ambra Roth (officer) may sell up to 9,497 shares (~$2.0 million) on or about November 9, 2026.

    On GestorLens

    • 9 concentrated managers (+1 this quarter)
    • 661 13F filers
    GestorLens profile
  • Genuine Parts

    GPC
    • 16:33 ETDividends and buybacksSEC 8-K 8.01

      Dividends and buybacks

      Other events.

      Company headline: “Genuine Parts Company Declares Regular Quarterly Dividend”

      From the company's release
      Genuine Parts Company Declares Regular Quarterly Dividend ATLANTA – Genuine Parts Company (NYSE: GPC), a leading global service provider of automotive and industrial replacement parts and value-added solutions, announced today its Board of Directors declared a regular quarterly cash dividend of one dollar and six and one quarter cents ($1.0625) per share on the company’s common stock.

    On GestorLens

    • 8 concentrated managers
    • 1,081 13F filers

    Well-known investors: Seth Klarman

    GestorLens profile
  • UnitedHealth Group

    UNH
    • 16:33 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      Company headline: “Madeline Bell Joins UnitedHealth Group Board of Directors”

      From the filing
      Ms. Bell will receive compensation for her services as a director in accordance with the Company’s standard compensation program for non-employee directors as amended from time to time, the material terms of which are described in the Company’s 2026 proxy statement.

    On GestorLens

    • 73 concentrated managers
    • 3,406 13F filers

    Well-known investors: Tiger Global, Soros Fund

    GestorLens profile
  • Perspective Therapeutics

    CATX
    • 16:33 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Results for the quarter ended September 30, 2026.

      Company headline: “Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results”

      Also: Other events

      From the company's release
      Cash, cash equivalents, and short-term investments as of September 30, 2026, were approximately $202 million as compared to approximately $145 million as of December 31, 2025.

    On GestorLens

    • 3 concentrated managers (-2 this quarter)
    • 129 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Viper Energy

    VNOM
    • 16:32 ET5%+ stakesSEC Schedule 13D/A

      Change in a 5%+ stake with activist intent

      Diamondback Energy and 2 related filers updated their stake: 43.1% (145,972,177 shares) (active, 13D) as of November 5, 2026.

      Filed by: Diamondback Energy, Inc.

    On GestorLens

    • 5 concentrated managers
    • 496 13F filers
    • 1 13D filings in the last year

    Well-known investors: Howard Marks

    GestorLens profile
  • Vestis

    VSTS
    • 16:30 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      John Laveck resigns as Vice President and Chief Accounting Officer, and principal accounting officer, effective December 11, 2026.

      From the filing
      On November 4, 2026, John Laveck notified Vestis Corporation (the “Company”) of his intention to resign as the Company’s Vice President and Chief Accounting Officer, and principal accounting officer, effective December 11, 2026, to pursue an opportunity outside of the Company’s industry.

    On GestorLens

    • 7 concentrated managers (+2 this quarter)
    • 283 13F filers
    • 1 insider bought in 180 days ($1M)
    • 1 13D filings in the last year
    GestorLens profile
  • Apple

    AAPL
    • 16:30 ETOtherSEC 8-K 8.01

      Other events

      From the filing
      On November 9, 2026, Apple Inc. (“Apple”) consummated the issuance and sale of $500,000,000 aggregate principal amount of its Floating Rate Notes due 2028 (the “2028 Floating Rate Notes”), $750,000,000 aggregate principal amount of its Floating Rate Notes due 2029 (the “2029 Floating Rate Notes”), $1,000,000,000 aggregate principal amount of its 4.650% Notes due 2028 (the “2028 Fixed Rate Notes”)…

    On GestorLens

    • 187 concentrated managers
    • 6,164 13F filers

    Well-known investors: Berkshire Hathaway, Markel Group, Soros Fund, Li Lu and 3 more

    GestorLens profile
  • KBR

    KBR
    • 16:30 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      Company headline: “KBR Announces Future Board of Directors for Trinzic”

      Also: Regulation FD disclosure

      From the filing
      As previously announced, KBR, Inc. (“KBR”) intends to separate its Mission Technology Solutions business into an independent, publicly traded company, Trinzic, Inc. (“Trinzic”), through a pro rata distribution of at least 80.1% of the outstanding shares of Trinzic common stock to KBR’s stockholders (the “Spin-Off”)…

    On GestorLens

    • 4 concentrated managers
    • 362 13F filers
    • 4 insiders bought in 180 days ($945,160)
    GestorLens profile
  • Armstrong World Industries

    AWI
    • 16:30 ETOtherSEC 8-K 7.01

      Regulation FD disclosure

      Company headline: “Armstrong World Industries to Attend the 2026 Baird Global Industrial Conference”

      From the company's release
      Armstrong World Industries, Inc. (NYSE:AWI), a leader in the design and manufacture of innovative interior and exterior architectural applications including ceilings, specialty walls, and exterior metal solutions…

    On GestorLens

    • 4 concentrated managers
    • 478 13F filers
    GestorLens profile
  • LCI Industries

    LCII
    • 16:30 ETMergers and tender offersSEC 425

      Communication about a merger or acquisition

      LCI Industries filed a communication about its merger.

    On GestorLens

    • 360 13F filers
    GestorLens profile
  • Cryoport

    CYRX
    • 16:30 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Daniel M Hancock (director) may sell up to 74,379 shares (~$1.4 million, 0.15% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 4 concentrated managers (+1 this quarter)
    • 183 13F filers
    GestorLens profile
  • Upstart Holdings

    UPST
    • 16:30 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      Natalia Mirgorodskaya resigns as Chief Accounting Officer, effective November 30, 2026.

      From the filing
      On November 3, 2026, Natalia Mirgorodskaya informed Upstart Holdings, Inc. (the “Company”) of her intent to resign as the Company’s Chief Accounting Officer (Principal Accounting Officer), effective as of November 30, 2026, to pursue another opportunity.

    On GestorLens

    • 3 concentrated managers (-1 this quarter)
    • 370 13F filers
    • 1 insider bought in 180 days ($2.7M)

    Well-known investors: Coatue

    GestorLens profile
  • Datadog

    DDOG
    • 16:30 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Alexis T Lequoc (director, officer) may sell up to 49,961 shares (~$8.9 million) on or about November 9, 2026.

    On GestorLens

    • 21 concentrated managers (+5 this quarter)
    • 1,282 13F filers

    Well-known investors: Soros Fund

    GestorLens profile
  • Beta Bionics

    BBNX
    • 16:30 ET5%+ stakesSEC Schedule 13G/A

      Change in a passive 5%+ stake

      Levy Guy and 8 related filers updated their stake: 8.7% (4,828,619 shares) (passive, 13G) as of September 30, 2026.

      Filed by: Soleus Capital Master Fund, L.P.

    On GestorLens

    • 6 concentrated managers (+1 this quarter)
    • 130 13F filers
    GestorLens profile
  • Evolus

    EOLS
    • 16:30 ET5%+ stakesSEC Schedule 13G/A

      Change in a passive 5%+ stake

      Soleus Capital Master Fund and 5 related filers updated their stake: 7.7% (5,090,000 shares) (passive, 13G) as of September 30, 2026.

      Filed by: Soleus Capital Master Fund, L.P.

    On GestorLens

    • 3 concentrated managers (-3 this quarter)
    • 157 13F filers
    GestorLens profile
  • Inspire Medical Systems

    INSP
    • 16:30 ET5%+ stakesSEC Schedule 13G/A

      Change in a passive 5%+ stake

      Soleus Capital Master Fund and 5 related filers report a 4.2% stake (1,206,828 shares), below 5% as of September 30, 2026.

      Filed by: Soleus Capital Master Fund, L.P.

    On GestorLens

    • 6 concentrated managers (-1 this quarter)
    • 275 13F filers
    GestorLens profile
  • NovoCure

    NVCR2 filings
    • 16:30 ET5%+ stakesSEC Schedule 13G/A

      Change in a passive 5%+ stake

      Soleus Capital Master Fund and 5 related filers updated their stake: 8.1% (9,425,776 shares) (passive, 13G) as of September 30, 2026.

      Filed by: Soleus Capital Master Fund, L.P.

    • 06:59 ETOtherSEC 8-K 7.01

      Regulation FD disclosure

      Company headline: “Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer”

      From the company's release
      Novocure (Nasdaq: NVCR) announced today that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) application for Optune Mya® for the treatment of adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation.

    On GestorLens

    • 3 concentrated managers (-2 this quarter)
    • 219 13F filers
    GestorLens profile
  • Palisade Bio

    PALI
    • 16:30 ET5%+ stakesSEC Schedule 13G/A

      Change in a passive 5%+ stake

      Soleus Capital Master Fund and 5 related filers updated their stake: 8.6% (14,996,154 shares) (passive, 13G) as of September 30, 2026.

      Filed by: Soleus Capital Master Fund, L.P.

    On GestorLens

    • 8 concentrated managers
    • 124 13F filers
    • 2 insiders bought in 180 days ($278,900)
    GestorLens profile
  • Green DOT

    GDOT
    • 16:27 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “Green Dot Reports Third Quarter 2026 Results”

      From the company's release
      Cash at the holding company was approximately $38 million as of September 30, 2026.

    On GestorLens

    • 3 concentrated managers
    • 161 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Trevi Therapeutics

    TRVI
    • 16:26 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Results for the quarter ended September 30, 2026.

      Company headline: “Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates”

      From the company's release
      The Company initiated the Phase 2b LAKE trial in patients with RCC in the second quarter of 2026 and enrollment is progressing. The trial provides for a sample size-re-estimation (SSRE) analysis once 50% of the patients complete treatment.

    On GestorLens

    • 17 concentrated managers (+2 this quarter)
    • 218 13F filers
    • 1 13D filings in the last year

    Well-known investors: Viking Global

    GestorLens profile
  • Office Properties Income Trust

    OPI
    • 16:25 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “Office Properties Income Trust Announces Third Quarter 2026 Results”

      From the company's release
      Office Properties Income Trust Announces Third Quarter 2026 Results

    On GestorLens

    • 1 concentrated managers (+1 this quarter)
    • 32 13F filers
    • 2 13D filings in the last year

    Well-known investors: Howard Marks

    GestorLens profile
  • Black Stone Minerals

    BSM
    • 16:25 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Lacy Properties (director) may sell up to 646,058 shares (~$8.7 million, 0.3% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 6 concentrated managers
    • 200 13F filers
    • 2 insiders bought in 180 days ($1.5M)
    GestorLens profile
  • Vistra Operations

    VST

    On GestorLens

    • 27 concentrated managers (+1 this quarter)
    • 1,414 13F filers
    • 1 insider bought in 180 days ($1.2M)

    Well-known investors: David Tepper, Soros Fund

    GestorLens profile
  • East West Bancorp

    EWBC
    • 16:22 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Dominic Ng (officer) may sell up to 34,977 shares (~$4.6 million) on or about November 9, 2026.

    On GestorLens

    • 7 concentrated managers (+1 this quarter)
    • 655 13F filers

    Well-known investors: Li Lu

    GestorLens profile
  • Humana

    HUM2 filings
    • 16:22 ETOtherSEC 8-K 8.01

      Other events

      Company headline: “Humana Commences Offers to Purchase for Cash Certain of its Outstanding Debt Securities”

      From the company's release
      Humana Inc. (NYSE: HUM) (“Humana”, “we”, or “our”) today announced that it has commenced cash tender offers (collectively, the “Offers”) to purchase the outstanding notes described below, in each case upon the terms and subject to the conditions set forth in the Offer to Purchase dated November 9, 2026 (the “Offer to Purchase”).
    • 09:31 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Joseph C Ventura (officer) may sell up to 5,495 shares (~$2.4 million) on or about November 9, 2026.

    On GestorLens

    • 18 concentrated managers (-1 this quarter)
    • 930 13F filers

    Well-known investors: Soros Fund

    GestorLens profile
  • Edwards Lifesciences

    EW2 filings
    • 16:21 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Bernard J Zovighian (officer, director) may sell up to 46,200 shares (~$4.8 million) on or about November 9, 2026.

    • 16:20 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Donald E Bobo Jr (officer) may sell up to 48,900 shares (~$5.0 million) on or about November 9, 2026.

    On GestorLens

    • 18 concentrated managers (-1 this quarter)
    • 1,337 13F filers
    GestorLens profile
  • Host Hotels & Resorts

    HST2 filings
    • 16:20 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Nathan Tyrrell (officer) may sell up to 50,000 shares (~$1.3 million) on or about November 9, 2026.

    • 16:19 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: James F Risoleo (officer) may sell up to 659,574 shares (~$16.7 million, 0.1% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 5 concentrated managers
    • 744 13F filers
    GestorLens profile
  • Lumen Technologies

    LUMN
    • 16:20 ETInsider buyingSEC Form 4 (P)

      Open-market purchase by an insider

      Kathleen E Johnson (Chief Executive Officer) bought 100,000 shares for $396,890 (avg. $3.97).

    On GestorLens

    • 1 concentrated managers (+1 this quarter)
    • 623 13F filers
    • 1 insider bought in 180 days ($613,000)
    GestorLens profile
  • Coherus Oncology

    CHRS
    • 16:20 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan”

      From the company's release
      Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan – Focus development efforts on tagmokitug/toripalimab as a potential best-in-disease treatment for esophageal cancer with plans for expedited development – – Deprioritize development of tagmokitug/toripalimab in other indications to allocate resources toward advancing the lead indication – – Right-sizing reduces…

    On GestorLens

    • 3 concentrated managers (-1 this quarter)
    • 146 13F filers
    GestorLens profile
  • Public Storage

    PSA
    • 16:19 ETOtherSEC 8-K 8.01

      Other events

      From the filing
      On November 9, 2026, Public Storage (the “Company”) filed a prospectus with the U.S. Securities and Exchange Commission (the “SEC”) relating to the potential resale, from time to time, by the selling securityholders named therein of up to 120,011 common shares of the Company.

    On GestorLens

    • 12 concentrated managers (+1 this quarter)
    • 1,130 13F filers
    GestorLens profile
  • Equinix

    EQIX
    • 16:19 ETOtherSEC 8-K 8.01

      Other events

      From the filing
      On November 9, 2026, Equinix Europe 2 Financing Corporation LLC (the “Issuer”), a Delaware limited liability company and an indirect, wholly-owned subsidiary of Equinix, Inc. (the “Guarantor” or “Equinix”), a Delaware corporation, issued and sold €650,000,000 aggregate principal amount of its 4.150% Senior Notes due 2028 (the “2028 Notes”)…

    On GestorLens

    • 27 concentrated managers (+4 this quarter)
    • 1,365 13F filers

    Well-known investors: Coatue, Stanley Druckenmiller

    GestorLens profile
  • Enphase Energy

    ENPH
    • 16:19 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Rodgers Massey Revocable Living Trust (director) may sell up to 300,000 shares (~$8.8 million, 0.23% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 7 concentrated managers
    • 537 13F filers
    • 2 insiders bought in 180 days ($689,476)

    Well-known investors: Coatue

    GestorLens profile
  • FedEx

    FDX
    • 16:18 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      Katherine M. Boyle joins the board.

      Company headline: “Katherine M. Boyle, General Partner, Andreessen Horowitz, Elected to FedEx Board of Directors”

      From the filing
      On November 9, 2026, the Board of Directors (the “Board”) of FedEx Corporation (“FedEx”) elected Katherine M. Boyle as a director, effective immediately.

    On GestorLens

    • 16 concentrated managers (-3 this quarter)
    • 1,969 13F filers

    Well-known investors: Gates Foundation Trust, Viking Global

    GestorLens profile
  • Surrozen

    SRZN
    • 16:18 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update”

      From the company's release
      First patient dosed in Phase 1b of DUET study evaluating SZN-8141 in patients with diabetic macular edema DUET Phase 2a enrollment to be expanded from approximately 60 to 150 patients to enable a more robust evaluation of SZN-8141 in DME Topline data from DUET Phase 1b expected in second half of 2027…

    On GestorLens

    • 4 concentrated managers (-1 this quarter)
    • 69 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Atlanta Braves Holdings

    BATRK
    • 16:18 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Michael P. Plant (officer) may sell up to 171,395 shares (~$8.8 million, 0.32% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 14 concentrated managers (+2 this quarter)
    • 322 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • ImageneBio

    IMA
    • 16:17 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Results for the quarter ended September 30, 2026.

      Company headline: “ImageneBio Reports Third Quarter 2026 Financial Results”

      From the company's release
      As of September 30, 2026, the Company held $126.6 million in cash, cash equivalents and marketable securities, providing anticipated funding for planned operations into the first quarter of 2028.

    On GestorLens

    • 3 concentrated managers
    • 35 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Atea Pharmaceuticals

    AVIR2 filings
    • 16:17 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update”

      From the company's release
      Chronic HCV infection remains an ongoing public health crisis. If left untreated, HCV can progress to cirrhosis, end-stage liver disease and liver cancer, and it remains one of the leading causes of liver cancer in the US, Europe and Japan.
    • 07:30 ETDeals and acquisitionsSEC 8-K 1.01

      Entry into a material agreement

      Also: New direct financial obligation

      From the filing
      On November 6, 2026 (the “Closing Date”), Atea Pharmaceuticals, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Agreement”) with Hercules Capital, Inc. (“Hercules”), as agent, and the lenders party thereto, providing for term loans in an aggregate principal amount of up to $200.0 million, subject to the terms and conditions set forth therein.

    On GestorLens

    • 4 concentrated managers
    • 124 13F filers
    • 1 insider bought in 180 days ($50,874)
    GestorLens profile
  • Lineage

    LINE
    • 16:17 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: loss per share of $0.68.

      Company headline: “Lineage, Inc. Reports Third-Quarter 2026 Financial Results”

      Also: Regulation FD disclosure

      From the company's release
      GAAP net loss of $(173) million, or $(0.68) per diluted common share

    On GestorLens

    • 6 concentrated managers (-1 this quarter)
    • 328 13F filers
    • 2 insiders bought in 180 days ($1.8M)
    GestorLens profile
  • Stryker

    SYK
    • 16:16 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      Company headline: “Stryker announces intention to nominate Jim Davis to board of directors”

      Also: Regulation FD disclosure

      From the filing
      On November 3, 2026, the Board of Directors of Stryker Corporation (the “Company”) increased the number of authorized directors from 11 to 12 and elected James E. Davis to fill the resulting vacancy.

    On GestorLens

    • 54 concentrated managers (+2 this quarter)
    • 2,268 13F filers
    • 1 13D filings in the last year

    Well-known investors: Terry Smith

    GestorLens profile
  • Vericel

    VCEL
    • 16:16 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Joseph Anthony Mara Jr (officer) may sell up to 25,000 shares (~$1.5 million, 0.05% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 3 concentrated managers (+1 this quarter)
    • 322 13F filers
    GestorLens profile
  • Genworth Financial

    GNW
    • 16:15 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      From the filing
      As previously announced by Genworth Financial, Inc. (the “Company”) on October 13, 2026, Darren W. Woodell, the Company’s Vice President and Controller (Principal Accounting Officer), notified the Company of his intention to resign to pursue a new opportunity, effective in early November 2026.

    On GestorLens

    • 3 concentrated managers
    • 367 13F filers
    GestorLens profile
  • Annaly Capital Management

    NLY
    • 16:15 ETInsider buyingSEC Form 4 (P)

      Open-market purchase by an insider

      Scott Wede (director) bought 50,000 shares for $940,000 (avg. $18.80).

    On GestorLens

    • 1 concentrated managers (+1 this quarter)
    • 792 13F filers
    GestorLens profile
  • Netflix

    NFLX
    • 16:15 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Gregory K Peters (officer) may sell up to 27,312 shares (~$1.7 million) on or about November 9, 2026.

    On GestorLens

    • 84 concentrated managers (-10 this quarter)
    • 3,404 13F filers

    Well-known investors: Bill Ackman, Terry Smith, Coatue, Soros Fund and 2 more

    GestorLens profile
  • Senseonics Holdings

    SENS
    • 16:15 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: revenue of $19.6 million.

      Company headline: “Senseonics Holdings, Inc. Reports Third Quarter 2026 Financial Results”

      From the company's release
      Total revenue for the third quarter of 2026 was $19.6 million, an increase of approximately 140% compared to $8.1 million for the third quarter of 2025.

    On GestorLens

    • 4 concentrated managers (+1 this quarter)
    • 108 13F filers
    • 1 insider bought in 180 days ($251,435)
    GestorLens profile
  • National Health Investors

    NHI3 filings
    • 16:14 ETOtherSEC 8-K 7.01

      Regulation FD disclosure

      Company headline: “NHI Issues Investor Update”

      From the company's release
      National Health Investors, Inc. (NYSE: NHI) has issued the following investor update which can be found at:
    • 16:09 ETOtherSEC 8-K 7.01

      Regulation FD disclosure

      Company headline: “National Health Investors Q3 2026 Supplemental”

    • 16:07 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Results for the quarter ended September 30, 2026.

      Company headline: “NHI Announces Third Quarter 2026 Results”

      From the company's release
      “We have closed more than $395 million in investments year-to-date and expect to complete significant additional investments before year-end, with ample capital available to fund our current pipeline.

    On GestorLens

    • 2 concentrated managers (-1 this quarter)
    • 305 13F filers
    • 2 insiders bought in 180 days ($167,028)
    GestorLens profile
  • RYAN Specialty Holdings

    RYAN
    • 16:14 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Benjamin Miles Wuller (officer) may sell up to 50,000 shares (~$2.4 million) on or about November 9, 2026.

    On GestorLens

    • 9 concentrated managers
    • 370 13F filers
    • 5 insiders bought in 180 days ($4.6M)
    GestorLens profile
  • Harrow

    HROW
    • 16:13 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: revenue of $25.3 million.

      Company headline: “Harrow Announces Third Quarter 2026 Financial Results”

      Also: Regulation FD disclosure

      From the company's release
      Revenue of $25.3 million, up 62% sequentially and 15% year over year

    On GestorLens

    • 4 concentrated managers (+1 this quarter)
    • 222 13F filers
    • 4 insiders bought in 180 days ($468,720)
    GestorLens profile
  • Occidental Petroleum

    OXY
    • 16:13 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: EPS of $1.61 (adjusted: $1.91).

      Company headline: “Occidental Announces 3rd Quarter 2026 Results”

      From the company's release
      "We reached an important milestone in the third quarter, reducing principal debt to $10.0 billion after retiring $10.4 billion of debt since the beginning of this year," said Richard Jackson, President and Chief Executive Officer.

    On GestorLens

    • 14 concentrated managers
    • 1,241 13F filers
    • 1 insider bought in 180 days ($249,853)

    Well-known investors: Berkshire Hathaway

    GestorLens profile
  • Repay Holdings

    RPAY
    • 16:13 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “REPAY Reports Third Quarter 2026 Financial Results”

      Also: Regulation FD disclosure

      From the company's release
      During the fourth quarter of 2025, Net loss was impacted by a $138.9 million goodwill impairment loss, primarily related to the Consumer Payments segment. Further information about this non-cash impairment loss can be found in the Annual Report on Form 10-K for the year ended December 31, 2025.

    On GestorLens

    • 3 concentrated managers
    • 142 13F filers
    • 5 13D filings in the last year
    GestorLens profile
  • Casella Waste Systems

    CWST
    • 16:13 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: revenue of $559.2 million.

      Company headline: “CASELLA WASTE SYSTEMS, INC. ANNOUNCES THIRD QUARTER 2026 RESULTS”

      From the company's release
      Revenues were $559.2 million for the quarter, up $73.9 million, or up 15.2%, from the same period in 2025.

    On GestorLens

    • 3 concentrated managers
    • 418 13F filers
    GestorLens profile
  • HIMS & Hers Health

    HIMS2 filings
    • 16:13 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      From the filing
      On November 4, 2026, the board of directors (the “Board”) of Hims & Hers Health, Inc. (the “Company”) increased the size of the Board from nine to ten directors and appointed Dr. Andrew Huberman, 51, to fill the newly created directorship, effective immediately.
    • 16:11 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: revenue of $890.4 million.

      Company headline: “Hims & Hers Health, Inc. Reports Third Quarter 2026 Financial Results”

      Also: Other events

      From the company's release
      Revenue was $890.4 million for the third quarter of 2026 compared to $599.0 million for the third quarter of 2025, an increase of 49% year-over-year.

    On GestorLens

    • 4 concentrated managers (-1 this quarter)
    • 509 13F filers
    • 1 insider bought in 180 days ($1.2M)
    • 1 13D filings in the last year
    GestorLens profile
  • Draftkings

    DKNG
    • 16:12 ETInsider buyingSEC Form 4 (P)

      Open-market purchase by an insider

      Alan Wayne Ellingson (Chief Financial Officer) bought 18,908 shares for $349,987 (avg. $18.51).

    On GestorLens

    • 6 concentrated managers
    • 696 13F filers
    GestorLens profile
  • Quantum

    QMCO
    • 16:12 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Fiscal Q2 2027 (ended September 30, 2026) results: revenue of $91 million.

      Company headline: “Quantum Reports Fiscal Second Quarter 2027 Financial Results”

      From the company's release
      Revenue of $91.0 million, plus or minus $2 million

    On GestorLens

    • 61 13F filers
    • 1 13D filings in the last year

    Well-known investors: Howard Marks

    GestorLens profile
  • USA Rare Earth

    USAR
    • 16:12 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 (ended September 30, 2026) results.

      Company headline: “USA Rare Earth Reports Third Quarter 2026 Financial Results”

      From the company's release
      Successfully produced first light and heavy rare earth oxide samples for qualification: In July 2026, the Company announced that its hydrometallurgical facility in Wheat Ridge, Colorado, had successfully produced commercial-grade dysprosium (Dy) oxide and neodymium-praseodymium (NdPr) oxide samples from recycled rare earth magnet scrap, known in the industry as “swarf.”

    On GestorLens

    • 2 concentrated managers (-1 this quarter)
    • 399 13F filers
    • 2 13D filings in the last year

    Well-known investors: Soros Fund

    GestorLens profile
  • Surgery Partners

    SGRY2 filings
    • 16:12 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 (ended September 30, 2026) results.

      Company headline: “SURGERY PARTNERS, INC. ANNOUNCES THIRD QUARTER 2026 RESULTS”

      From the company's release
      On November 9, 2026, Surgery Partners announced an amendment to its previously announced merger agreement with HealthSpan Partners, following Surgery Partners’ receipt of an unsolicited competing proposal from a third party.
    • 09:15 ETDeals and acquisitionsSEC 8-K 1.01

      Entry into a material agreement

      Company headline: “Surgery Partners and HealthSpan Partners Announce Amended Merger Agreement, Following Receipt of Unsolicited Proposal”

      Also: Regulation FD disclosure

      From the filing
      On November 8, 2026, Surgery Partners, Inc., a Delaware corporation (the “Company”), entered into Amendment No. 1 to Agreement and Plan of Merger (the “Amendment”) with Spyglass Topco, LLC, a Delaware limited liability company (“Parent”), Spyglass Merger Subsidiary, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Subsidiary”), and, solely for the limited purposes set forth therein…

    On GestorLens

    • 2 concentrated managers (-1 this quarter)
    • 189 13F filers
    • 1 insider bought in 180 days ($161,212)
    • 1 13D filings in the last year

    Well-known investors: Howard Marks

    GestorLens profile
  • H&r Block

    HRB
    • 16:11 ETDividends and buybacksSEC 8-K 2.02

      Dividend announcement

      Quarterly dividend of $0.46 per share, payable January 6, 2027 to shareholders of record on December 3, 2026.

      Company headline: “H&R Block Reports Fiscal 2027 First Quarter Results and Reaffirms Fiscal 2027 Outlook”

      Also: Regulation FD disclosure

      From the filing
      On November 9, 2026, the Company announced that its Board of Directors declared a quarterly cash dividend of $0.46 per share, payable on January 6, 2027 to shareholders of record as of December 3, 2026.

    On GestorLens

    • 3 concentrated managers (-1 this quarter)
    • 542 13F filers
    GestorLens profile
  • Structure Therapeutics

    GPCR
    • 16:11 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      From the company's release
      In September 2026, the Company reported 72-week results from the ACCESS open-label extension (OLE), a prespecified 36-week extension of the Phase 2b ACCESS clinical trial designed to evaluate the longer-term safety and tolerability of aleniglipron and the durability of weight loss through 72 weeks of treatment.

    On GestorLens

    • 12 concentrated managers (-2 this quarter)
    • 192 13F filers
    GestorLens profile
  • Clearway Energy

    CWEN
    • 16:11 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “Clearway Energy, Inc. Reports Third Quarter 2026 Financial Results”

      From the company's release
      "Since last quarter, we have committed to two additional drop-downs from Clearway Energy Group LLC (“Clearway Group”), secured further revenue contracting for our Flexible Generation fleet at long contract tenors, and increased our committed and identified drop-down opportunities (which have increased by over 100% since the beginning of the year)…

    On GestorLens

    • 1 concentrated managers
    • 479 13F filers
    • 2 13D filings in the last year
    GestorLens profile
  • Take-two Interactive Software

    TTWO
    • 16:10 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Fiscal Q2 2027 results.

      Company headline: “Head of Global Corporate Communications”

      From the company's release
      Strauss Zelnick, Chairman and CEO of Take-Two Interactive, stated: “The launch of Grand Theft Auto VI is ten days away and, with pre-orders continuing to reach unprecedented levels, we expect to deliver an historic year for our company.

    On GestorLens

    • 11 concentrated managers (+2 this quarter)
    • 1,120 13F filers

    Well-known investors: Tiger Global, Viking Global

    GestorLens profile
  • ResMed

    RMD
    • 16:10 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Michael J. Farrell (officer, director) may sell up to 4,993 shares (~$1.2 million) on or about November 9, 2026.

    On GestorLens

    • 6 concentrated managers (-1 this quarter)
    • 891 13F filers

    Well-known investors: Giverny Capital

    GestorLens profile
  • Texas Instruments

    TXN
    • 16:10 ETOtherSEC 8-K 8.01

      Other events

      From the filing
      The Notes were offered pursuant to Texas Instruments’ Registration Statement on Form S-3 filed on February 14, 2025 (Reg. No. 333-284977), including the prospectus contained therein, and a related preliminary prospectus supplement dated October 26, 2026 and a prospectus supplement dated October 26, 2026.

    On GestorLens

    • 50 concentrated managers (+11 this quarter)
    • 2,870 13F filers

    Well-known investors: Terry Smith, Markel Group, Soros Fund

    GestorLens profile
  • GeneDx Holdings

    WGS
    • 16:10 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: revenue of $123.1 million.

      Company headline: “GeneDx Reports Third Quarter 2026 Financial Results”

      From the company's release
      Reported third quarter 2026 revenue of $123.1 million, including $110.4 million in exome and genome revenue

    On GestorLens

    • 8 concentrated managers (-1 this quarter)
    • 226 13F filers
    • 2 insiders bought in 180 days ($46.3M)
    • 1 13D filings in the last year
    GestorLens profile
  • Nisource

    NI
    • 16:10 ETOtherSEC 8-K 8.01

      Other events

      From the filing
      On November 2, 2026, NiSource Inc. (the “Company”) and BMO Capital Markets Corp., KeyBanc Capital Markets Inc., Mizuho Securities USA LLC and PNC Capital Markets LLC, as Lead Underwriters, entered into a Terms Agreement (the “Terms Agreement”) with respect to the offering and sale of $600,000,000 aggregate principal amount of the Company’s 5.400% Notes due 2032 (the “Notes”) under the Company’s Registration…

    On GestorLens

    • 5 concentrated managers
    • 915 13F filers
    GestorLens profile
  • Fortune Brands Innovations

    FBIN
    • 16:10 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      Victor Grizzle joins the board, effective January 1, 2027.

      Company headline: “Fortune Brands Elects Victor Grizzle to Board of Directors”

      Also: Regulation FD disclosure

      From the filing
      On November 6, 2026, the Board of Directors (the “Board”) of Fortune Brands Innovations, Inc. (“Fortune Brands” or the “Company”) elected Mr. Victor Grizzle as a Class I member of the Board, effective January 1, 2027.

    On GestorLens

    • 8 concentrated managers (+2 this quarter)
    • 532 13F filers
    • 2 insiders bought in 180 days ($30.7M)
    • 1 13D filings in the last year

    Well-known investors: David Einhorn

    GestorLens profile
  • Crescent Capital BDC

    CCAP
    • 16:10 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “Crescent Capital BDC, Inc. Reports Third Quarter 2026 Earnings Results; Declares a Fourth Quarter Base Dividend of $0.34 Per Share and Announces a $50 Million Share Repurchase Program”

      From the company's release
      Crescent Capital BDC, Inc. (“Crescent BDC” or “Company”) (NASDAQ: CCAP) today reported net investment income of $0.37 per share and net income of $0.27 per share for the quarter ended September 30, 2026.

    On GestorLens

    • 3 concentrated managers
    • 85 13F filers
    • 4 insiders bought in 180 days ($1.1M)
    GestorLens profile
  • Definium Therapeutics

    DFTX
    • 16:10 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights”

      From the company's release
      Cash, Cash Equivalents and Investments. As of September 30, 2026, the Company had cash, cash equivalents and investments of approximately $1.05 billion compared to $411.6 million as of December 31, 2025.

    On GestorLens

    • 16 concentrated managers (+6 this quarter)
    • 362 13F filers

    Well-known investors: Stanley Druckenmiller

    GestorLens profile
  • Autonation

    AN
    • 16:09 ETInsider buyingSEC Form 4 (P)

      Open-market purchase by an insider

      Thomas A Szlosek (EVP & CFO) bought 1,081 shares for $199,800 (avg. $184.83).

    On GestorLens

    • 3 concentrated managers
    • 512 13F filers
    • 3 insiders bought in 180 days ($1.4M)
    • 1 13D filings in the last year
    GestorLens profile
  • MAZE Therapeutics

    MAZE
    • 16:09 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights”

      From the company's release
      Cash Position: Cash, cash equivalents and marketable securities were $477.0 million as of September 30, 2026, compared to $360.0 million as of December 31, 2025.

    On GestorLens

    • 7 concentrated managers (-3 this quarter)
    • 160 13F filers
    GestorLens profile
  • The Trade Desk

    TTD
    • 16:09 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “The Trade Desk Reports Third Quarter 2026 Financial Results”

      Also: Other events

      From the company's release
      The Trade Desk also announced a $731 million increase to its share repurchase authorization, bringing the total amount available for future repurchases to $1 billion of its Class A common stock.

    On GestorLens

    • 2 concentrated managers (-3 this quarter)
    • 685 13F filers

    Well-known investors: Coatue

    GestorLens profile
  • Quantum Computing

    QUBT
    • 16:09 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: revenue of $9.5 million.

      Company headline: “Quantum Computing Inc. Reports Third Quarter 2026 Financial Results”

      From the company's release
      Quantum Computing Inc. ("QCi" or the "Company") (Nasdaq: QUBT), a vertically integrated quantum company pioneering photonics and semiconductor manufacturing, today announced financial results for the third quarter ended September 30, 2026.

    On GestorLens

    • 314 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • AAON

    AAON
    • 16:09 ETEarningsSEC 8-K 4.02

      Prior financial statements can no longer be relied on

      Q3 2026 results: revenue of $707.4 million; EPS of $0.83 (adjusted: $0.83).

      Company headline: “The Aaon Group Reports Record Third Quarter 2026 Results, Restates First and Second Quarter 2026 Financial Statements and Raises Full-Year Outlook”

      Also: Results of operations and financial condition; Regulation FD disclosure

      From the company's release
      Net sales increased 84.1% to a record $707.4 million

    On GestorLens

    • 6 concentrated managers (-1 this quarter)
    • 475 13F filers
    • 2 insiders bought in 180 days ($109,584)

    Well-known investors: Giverny Capital

    GestorLens profile
  • Zentalis Pharmaceuticals

    ZNTL
    • 16:08 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates”

      Also: Regulation FD disclosure

      From the company's release
      “With $228.9 million on the balance sheet providing an anticipated runway into the first half of 2028, we believe we are well resourced to support key DENALI milestones, full enrollment in ASPENOVA and combination trials in ovarian cancer and triple-negative breast cancer,” Ms. Eastland concluded.

    On GestorLens

    • 3 concentrated managers (+1 this quarter)
    • 115 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Trump Media & Technology Group

    DJT2 filings
    • 16:08 ETMergers and tender offersSEC 425

      Communication about a merger or acquisition

    • 16:08 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “Trump Media & Technology Group Reports Third Quarter 2026 Results”

      From the company's release
      TMTG closed the third quarter of 2026 with total assets of $2.5 billion and financial assets* of approximately $2.3 billion comprising cash, restricted cash, short-term investments, equity securities, note receivable and accrued interest, digital assets, and digital assets pledged.

    On GestorLens

    • 327 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Ameresco

    AMRC
    • 16:08 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: revenue of $580.3 million; EPS of $0.59 (adjusted: $0.88).

      Company headline: “Ameresco Reports Third Quarter 2026 Financial Results”

      From the company's release
      “Our third quarter results represented another quarter of strong growth and disciplined execution. We achieved revenue increases across each of our major business lines, expanded margins and continued to build both awarded and contracted backlogs.

    On GestorLens

    • 3 concentrated managers
    • 183 13F filers
    • 4 insiders bought in 180 days ($1.9M)
    GestorLens profile
  • Larimar Therapeutics

    LRMR
    • 16:08 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Company headline: “Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia”

      Also: Other events

      From the filing
      On November 9, 2026, Larimar Therapeutics, Inc. (the “Company”) disclosed in an updated slide presentation, posted on its website, that, as of September 30, 2026, the Company had approximately $128.7 million of cash, cash equivalents and marketable securities.

    On GestorLens

    • 5 concentrated managers (+1 this quarter)
    • 163 13F filers
    • 1 insider bought in 180 days ($167,000)
    • 1 13D filings in the last year
    GestorLens profile
  • Qualys

    QLYS
    • 16:08 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: revenue of $188 million; EPS of $1.62 (adjusted: $2.12).

      Company headline: “Qualys Announces Third Quarter 2026 Financial Results”

      From the company's release
      For the quarter, the Company reported revenues of $188.0 million, net income under United States Generally Accepted Accounting Principles ("GAAP") of $57.2 million, non-GAAP net income of $74.8 million, Adjusted EBITDA of $89.9 million, GAAP net income per diluted share of $1.62, and non-GAAP net income per diluted share of $2.12.

    On GestorLens

    • 4 concentrated managers
    • 436 13F filers
    GestorLens profile
  • Lucid Group

    LCID
    • 16:08 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: revenue of $350 million.

      From the company's release
      Lucid reported third quarter revenue of $350 million, up 4% year over-year in a US BEV market down 41% over the same period1, and significantly improved gross profit margin.

    On GestorLens

    • 1 concentrated managers
    • 374 13F filers
    • 1 13D filings in the last year

    Well-known investors: Soros Fund, Coatue

    GestorLens profile
  • Zymeworks

    ZYME
    • 16:08 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results”

      Also: Regulation FD disclosure

      From the company's release
      Royalty revenue from Jazz Pharmaceuticals (Jazz) and BeOne Medicines (BeOne) was $2.3 million in the three months ended September 30, 2026, driven primarily by net product sales of Ziihera by Jazz in the United States.

    On GestorLens

    • 6 concentrated managers (-3 this quarter)
    • 203 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • ONTO Innovation

    ONTO
    • 16:08 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: revenue of $409.7 million; EPS of $0.95 (adjusted: $2.44).

      Company headline: “Onto Innovation Reports 2026 Third Quarter Results”

      From the company's release
      Revenue of $409.7 million, an increase of 87.8% year-over-year from $218.2 million in the third quarter of 2025.

    On GestorLens

    • 12 concentrated managers (-1 this quarter)
    • 694 13F filers
    GestorLens profile
  • Artiva Biotherapeutics

    ARTV
    • 16:07 ETOtherSEC 8-K/A 2.05

      Exit or restructuring costs

      Restructuring plan: about 94% workforce reduction.

      From the filing
      On October 27, 2026, Artiva Biotherapeutics, Inc. (the "Company") filed a Current Report on Form 8-K (the "Original 8-K") with the Securities and Exchange Commission (the "SEC") disclosing that the Company's board of directors approved the discontinuation of the Company's development of AlloNK® (AB-101), its non-genetically modified, allogeneic natural killer (NK) cell therapy candidate…

    On GestorLens

    • 6 concentrated managers (+4 this quarter)
    • 72 13F filers
    • 1 insider bought in 180 days ($109.1M)
    • 2 13D filings in the last year

    Well-known investors: Viking Global

    GestorLens profile
  • PLUG Power

    PLUG
    • 16:07 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “Third Quarter Revenue of ~$201 Million, ~65 Percentage Point YoY Gross Margin Improvement, Record-Low Net Cash Usage with ~54% reduction sequentially”

      From the company's release
      Basic EPS was approximately $0.07, compared with $(0.31) in the prior-year period. The results for Q3 included non-cash mark-to-market gains associated with equity instruments of ~$192 million, or approximately $0.12 positive of an impact.

    On GestorLens

    • 2 concentrated managers
    • 511 13F filers

    Well-known investors: Coatue

    GestorLens profile
  • Archer Aviation

    ACHR
    • 16:07 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Company headline: “UNLOCK THE SKIES Q3 2026 SHAREHOLDER LETTER | 1 Q3 2026”

      From the filing
      The Company makes or will make reference to non-GAAP financial information in the Press Release and on the conference call. A reconciliation of GAAP to non-GAAP results is provided in the Press Release, as attached to this Current Report on Form 8-K.

    On GestorLens

    • 2 concentrated managers
    • 527 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Iheartmedia

    IHRT
    • 16:07 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Results for the quarter ended September 30, 2026: revenue of $1.03 billion.

      Company headline: “IHEARTMEDIA, INC. REPORTS RESULTS FOR 2026 THIRD…”

      From the company's release
      Q3 Revenue of $1,030 million, up 3.3% (Excluding Q3 Political Revenue, Q3 Revenue up 0.9%)

    On GestorLens

    • 3 concentrated managers
    • 133 13F filers
    GestorLens profile
  • AbbVie

    ABBV
    • 16:06 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Jeffrey R Stewart (officer) may sell up to 40,619 shares (~$11.9 million) on or about November 9, 2026.

    On GestorLens

    • 69 concentrated managers (+2 this quarter)
    • 4,248 13F filers
    GestorLens profile
  • Rocket Lab

    RKLB
    • 16:06 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      From the company's release
      Rocket Lab founder and CEO, Sir Peter Beck, says: “Q3 2026 was a defining quarter for Rocket Lab. We delivered a record $268 million in revenue ($34 million higher than Q2 2026) alongside a record backlog which has grown to $3.57 billion.

    On GestorLens

    • 6 concentrated managers (+2 this quarter)
    • 1,124 13F filers
    • 2 13D filings in the last year
    GestorLens profile
  • SOPHiA GENETICS

    SOPH2 filings
    • 16:06 ETInsider buyingSEC Form 4 (P)

      Open-market purchase by an insider

      George Cardoza (Chief Financial Officer) bought 20,000 shares for $141,200 (avg. $7.06).

    • 16:05 ETInsider buyingSEC Form 4 (P)

      Open-market purchase by an insider

      Ross Muken (Chief Executive Officer) bought 20,000 shares for $137,188 (avg. $6.86).

    On GestorLens

    • 4 concentrated managers
    • 72 13F filers
    • 1 insider bought in 180 days ($99,000)

    Well-known investors: Akre Capital

    GestorLens profile
  • Sanmina

    SANM
    • 16:05 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Fiscal Q4 (ended October 3, 2026) results.

      Company headline: “Sanmina Reports Fourth Quarter and Fiscal 2026 Financial Results”

      Also: Other events

      From the company's release
      “Our fiscal 2026 results were exceptional. Revenue grew 79%, non-GAAP operating profit increased 130%, and non-GAAP diluted earnings per share more than doubled compared to a year ago.

    On GestorLens

    • 2 concentrated managers (+2 this quarter)
    • 576 13F filers
    GestorLens profile
  • Thryv Holdings

    THRY
    • 16:05 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: revenue of $118.9 million.

      Company headline: “Thryv Reports Third Quarter 2026 Results, Focuses on Execution as a Pure-Play SaaS Business”

      Also: Regulation FD disclosure

      From the company's release
      Consolidated total revenue was $118.9 million

    On GestorLens

    • 4 concentrated managers (+1 this quarter)
    • 127 13F filers
    • 1 insider bought in 180 days ($1.2M)
    GestorLens profile
  • Arrivent Biopharma

    AVBP
    • 16:05 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 (ended September 30, 2026) results.

      Company headline: “ArriVent BioPharma Reports Third Quarter 2026”

      Also: Departure or appointment of directors or officers

      From the company's release
      At 240 mg, firmonertinib demonstrated median PFS of 11.0 months versus 9.5 months with chemotherapy (HR 0.75; p=0.0654), a confirmed objective response rate by BICR of 60% versus 33%, and a safety profile consistent with prior studies.

    On GestorLens

    • 6 concentrated managers
    • 156 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Estée Lauder

    EL2 filings
    • 16:05 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Rashida la Lande (officer) may sell up to 8,879 shares (~$1.0 million) on or about November 9, 2026.

    • 16:04 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Stephane Renaud Dela Faverie (officer) may sell up to 9,100 shares (~$1.0 million) on or about November 9, 2026.

    On GestorLens

    • 13 concentrated managers (+2 this quarter)
    • 829 13F filers
    • 3 13D filings in the last year
    GestorLens profile
  • Digital Turbine

    APPS
    • 16:05 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Fiscal Q2 (ended September 30, 2026) results: revenue of $178.7 million; EPS of $0.06.

      Company headline: “Digital Turbine Reports Strong Fiscal 2027 Second Quarter Financial Results”

      From the company's release
      Second Quarter Net Revenue Totaled $178.7 Million, Representing Year-over-Year Growth of 27% Second Quarter GAAP Net Income of $10.3 Million and diluted GAAP EPS of $0.06

    On GestorLens

    • 3 concentrated managers (+1 this quarter)
    • 211 13F filers
    GestorLens profile
  • Zeta Global Holdings

    ZETA
    • 16:05 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 (ended September 30, 2026) results: revenue of $493 million; EPS of $0.14 (adjusted: $0.38).

      Company headline: “Zeta Global Reports 21st Consecutive “Beat and Raise” Quarter, Generates Positive GAAP Net Income in 3Q’26 & YTD, and Achieves the Rule of 71”

      From the company's release
      Delivered revenue of $493 million for the third quarter, an increase of 46% Y/Y or 30% Y/Y excluding Marigold and political candidate revenue, an acceleration from 28% growth excluding Marigold last quarter.

    On GestorLens

    • 6 concentrated managers (-2 this quarter)
    • 416 13F filers

    Well-known investors: Soros Fund

    GestorLens profile
  • Annexon

    ANNX
    • 16:05 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: loss per share of $0.25.

      Company headline: “Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones”

      From the company's release
      Net loss: Net loss attributable to common stockholders was $51.2 million or $0.25 per share for the quarter ended September 30, 2026, compared to $54.9 million or $0.37 per share for the quarter ended September 30, 2025.

    On GestorLens

    • 13 concentrated managers (-1 this quarter)
    • 216 13F filers
    • 3 insiders bought in 180 days ($3.5M)
    • 1 13D filings in the last year
    GestorLens profile
  • Immunome

    IMNM
    • 16:05 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update”

      From the company's release
      Among 11 response-evaluable patients with diffuse large B-cell lymphoma (DLBCL), the objective response rate was 64% (7/11), including three complete responses.

    On GestorLens

    • 7 concentrated managers (+1 this quarter)
    • 203 13F filers
    • 1 insider bought in 180 days ($307,760)
    • 1 13D filings in the last year
    GestorLens profile
  • MBX Biosciences

    MBX
    • 16:05 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights”

      Also: Regulation FD disclosure

      From the company's release
      Enrollment in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway 12-week MAD (Part C, Cohort 1) data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity designed for once-monthly dosing, on track for Q4 2026 Preclinical data for MBX 6180, a GLP-1/GIP/GCG triple agonist prodrug with potential for once-monthly dosing…

    On GestorLens

    • 11 concentrated managers (+1 this quarter)
    • 172 13F filers
    • 3 13D filings in the last year
    GestorLens profile
  • MARA Holdings

    MARA
    • 16:05 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Company headline: “Financial and Operational Discussion”

      From the company's release
      Exaion signed a four-year $79M GPU-as-a-service contract on 100% take-or-pay terms with its first US customer. Customer demand has built a pipeline of over $3 billion in total contract value, with approximately $1 billion of that targeted for delivery by the end of 2027.

    On GestorLens

    • 2 concentrated managers (-1 this quarter)
    • 413 13F filers
    GestorLens profile
  • BALL

    BALL
    • 16:04 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Kathleen E Pitre may sell up to 30,245 shares (~$2.0 million) on or about November 9, 2026.

    On GestorLens

    • 3 concentrated managers (-1 this quarter)
    • 802 13F filers
    GestorLens profile
  • Royal Caribbean Cruises

    RCL
    • 16:04 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: As Awilhelmsen (director) may sell up to 500,000 shares (~$170.5 million, 0.19% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 8 concentrated managers (+1 this quarter)
    • 1,236 13F filers
    GestorLens profile
  • Septerna

    SEPN
    • 16:04 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results”

      From the company's release
      Under its global collaboration with Novo, initiated in July 2025, Septerna and Novo are advancing oral small molecule programs for obesity, type 2 diabetes and other cardiometabolic diseases.

    On GestorLens

    • 8 concentrated managers (-3 this quarter)
    • 155 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • TEVA Pharmaceutical Industries

    TEVA
    • 16:03 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Richard Daniell may sell up to 25,000 shares (~$1.1 million) on or about November 9, 2026.

    On GestorLens

    • 11 concentrated managers
    • 677 13F filers

    Well-known investors: David Einhorn, Stanley Druckenmiller

    GestorLens profile
  • Goosehead Insurance

    GSHD
    • 16:02 ETEarningsSEC 8-K 4.02

      Prior financial statements can no longer be relied on

      Non-reliance on prior financial statements.

      Company headline: “GOOSEHEAD INSURANCE, INC. RELEASES PRELIMINARY THIRD QUARTER 2026 RESULTS”

      Also: Results of operations and financial condition

      From the filing
      In response to a comment letter received from the SEC as part of its standard review of our annual filings, management determined that its historical accounting for certain costs to obtain customer contracts did not conform to GAAP.

    On GestorLens

    • 3 concentrated managers
    • 229 13F filers
    • 5 insiders bought in 180 days ($19.3M)
    • 1 13D filings in the last year

    Well-known investors: Akre Capital

    GestorLens profile
  • SNAP

    SNAP
    • 16:01 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Robert C. Murphy (officer, director) may sell up to 2,000,000 shares (~$10 million, 0.14% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 2 concentrated managers (-1 this quarter)
    • 535 13F filers
    GestorLens profile
  • Xenon Pharmaceuticals

    XENE
    • 16:00 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 (ended September 30, 2026) results.

      Company headline: “Xenon Reports Q3 2026 Financial Results and Provides Business Update”

      Also: Regulation FD disclosure

      From the company's release
      Cash, cash equivalents and marketable securities were $1,153.5 million as of September 30, 2026, compared to $586.0 million as of December 31, 2025. Based on current operating plans, Xenon anticipates having sufficient cash to fund operations into 2029.

    On GestorLens

    • 16 concentrated managers (-3 this quarter)
    • 317 13F filers
    • 2 insiders bought in 180 days ($1.7M)

    Well-known investors: Stanley Druckenmiller

    GestorLens profile
  • Columbus McKinnon

    CMCO
    • 15:54 ETInsider buyingSEC Form 4 (P)

      Open-market purchase by an insider

      David J. Wilson (President & CEO) bought 32,631 shares for $551,349 (avg. $16.90).

    On GestorLens

    • 3 concentrated managers
    • 173 13F filers
    • 2 insiders bought in 180 days ($194,660)
    • 1 13D filings in the last year
    GestorLens profile
  • Aura Minerals

    AUGO
    • 15:34 ET5%+ stakesSEC Schedule 13G/A

      Change in a passive 5%+ stake

      Kapitalo Investimentos Ltda and 4 related filers report a 4.9% stake (4,111,703 shares), below 5% as of December 31, 2025.

      Filed by: Kapitalo Investimentos Ltda

    On GestorLens

    • 3 concentrated managers
    • 206 13F filers
    • 1 insider bought in 180 days ($22.8M)
    GestorLens profile
  • Astera Labs

    ALAB
    • 15:20 ETPlanned insider salesSEC Form 144/A

      Amended notice of proposed sale (Form 144)

      Notice of proposed sale: Stefan A Dyckerhoff (director) may sell up to 12,499 shares (~$2.6 million) on or about November 5, 2026.

    On GestorLens

    • 15 concentrated managers (+6 this quarter)
    • 992 13F filers
    GestorLens profile
  • United Airlines Holdings

    UAL2 filings
    • 15:18 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Kate Gebo (officer) may sell up to 28,283 shares (~$3.4 million) on or about November 9, 2026.

    • 15:08 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Kate Gebo (family member of an insider) may sell up to 11,717 shares (~$1.4 million) on or about November 9, 2026.

    On GestorLens

    • 16 concentrated managers
    • 1,072 13F filers

    Well-known investors: Stanley Druckenmiller

    GestorLens profile
  • Travel & Leisure

    TNL

    On GestorLens

    • 6 concentrated managers (+1 this quarter)
    • 477 13F filers
    GestorLens profile
  • Barnes Group

    B
    • 14:58 ETEarningsSEC 6-K

      Foreign issuer report

      Q3 2026 results.

      Company headline: “Barrick Reports Third Quarter 2026 Results”

      From the company's release
      Fourth straight quarter of strong operational delivery – Gold production of 816 thousand ounces1, up 3% from Q2 2026, and 6% year-over-year (excluding divested assets).2 – Strong operating performance across the portfolio: Cortez benefited from the continued Goldrush ramp-up, Carlin’s Gold Quarry roaster posted a record quarter, and Loulo-Gounkoto, in a strong ramp-up that remains ahead of schedule…

    On GestorLens

    • 11 concentrated managers (-3 this quarter)
    • 1,013 13F filers

    Well-known investors: Howard Marks

    GestorLens profile
  • CRH Public

    CRH

    On GestorLens

    • 26 concentrated managers (+2 this quarter)
    • 1,028 13F filers
    • 1 insider bought in 180 days ($189,260)

    Well-known investors: Dan Loeb, Stanley Druckenmiller, Soros Fund

    GestorLens profile
  • Sionna Therapeutics

    SION
    • 14:24 ET5%+ stakesSEC Schedule 13G

      New passive 5%+ stake

      the Goldman Sachs Group and 1 related filer reported a stake: 5.8% (2,639,418 shares) (passive, 13G) as of September 30, 2026.

      Filed by: GOLDMAN SACHS GROUP INC

    On GestorLens

    • 11 concentrated managers (+3 this quarter)
    • 146 13F filers
    • 2 13D filings in the last year

    Well-known investors: Viking Global

    GestorLens profile
  • Replimune Group

    REPL
    • 14:13 ET5%+ stakesSEC Schedule 13G/A

      Change in a passive 5%+ stake

      the Goldman Sachs Group and 1 related filer report a 3.3% stake (3,115,243 shares), below 5% as of September 30, 2026.

      Filed by: GOLDMAN SACHS GROUP INC

    On GestorLens

    • 6 concentrated managers
    • 200 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Qfin Holdings

    QFIN
    • 14:06 ET5%+ stakesSEC Schedule 13G

      New passive 5%+ stake

      the Goldman Sachs Group and 1 related filer reported a stake: 5.2% (12,603,798 shares) (passive, 13G) as of September 30, 2026.

      Filed by: GOLDMAN SACHS GROUP INC

    On GestorLens

    • 5 concentrated managers (+1 this quarter)
    • 156 13F filers
    • 1 insider bought in 180 days ($57,640)
    • 1 13D filings in the last year
    GestorLens profile
  • Hyperliquid Strategies

    PURR
    • 14:01 ET5%+ stakesSEC Schedule 13G

      New passive 5%+ stake

      the Goldman Sachs Group and 1 related filer reported a stake: 5.1% (12,115,117 shares) (passive, 13G) as of September 30, 2026.

      Filed by: GOLDMAN SACHS GROUP INC

    On GestorLens

    • 6 concentrated managers (+3 this quarter)
    • 178 13F filers

    Well-known investors: Stanley Druckenmiller

    GestorLens profile
  • Five Point Holdings

    FPH
    • 13:50 ET5%+ stakesSEC Schedule 13G/A

      Change in a passive 5%+ stake

      Private Management Group updated its stake: 8.4% (6,072,182 shares) (passive, 13G) as of September 30, 2026.

      Filed by: PRIVATE MANAGEMENT GROUP INC

    On GestorLens

    • 5 concentrated managers
    • 87 13F filers
    GestorLens profile
  • Linde

    LIN
    • 13:46 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Binod Patwari may sell up to 2,500 shares (~$1.3 million) on or about November 9, 2026.

    On GestorLens

    • 58 concentrated managers (+2 this quarter)
    • 2,335 13F filers
    • 1 insider bought in 180 days ($47,912)

    Well-known investors: Lone Pine, Soros Fund, Markel Group, Stanley Druckenmiller

    GestorLens profile
  • Karyopharm Therapeutics

    KPTI
    • 13:45 ET5%+ stakesSEC Schedule 13G/A

      Change in a passive 5%+ stake

      the Goldman Sachs Group and 1 related filer report a 0.9% stake (203,129 shares), below 5% as of September 30, 2026.

      Filed by: GOLDMAN SACHS GROUP INC

    On GestorLens

    • 5 concentrated managers (-2 this quarter)
    • 95 13F filers
    GestorLens profile
  • EVgo

    EVGO2 filings
    • 13:31 ET5%+ stakesSEC Schedule 13G/A

      Change in a passive 5%+ stake

      CIBC Private Wealth Group updated its stake: 5.6% (7,923,969 shares) (passive, 13G) as of November 5, 2026.

      Filed by: CIBC Private Wealth Group LLC

    • 12:22 ET5%+ stakesSEC Schedule 13G

      New passive 5%+ stake

      CIBC Private Wealth Group reported a stake: 5.1% (141,715,720 shares) (passive, 13G) as of November 5, 2026.

      Filed by: CIBC Private Wealth Group LLC

    On GestorLens

    • 2 concentrated managers (+1 this quarter)
    • 191 13F filers
    • 1 13D filings in the last year

    Well-known investors: Soros Fund

    GestorLens profile
  • Sutro Biopharma

    STRO
    • 13:23 ET5%+ stakesSEC Schedule 13G

      New passive 5%+ stake

      Coastlands Capital and 4 related filers reported a stake: 5.14% (852,669 shares) (passive, 13G) as of November 5, 2026.

      Filed by: Coastlands Capital LP

    On GestorLens

    • 3 concentrated managers (-2 this quarter)
    • 97 13F filers
    GestorLens profile
  • Ericsson LM Telephone

    ERIC
    • 13:20 ETDividends and buybacksSEC 6-K

      Foreign issuer report

      Company announcement.

      Company headline: “Share buybacks in Ericsson during the period November 2 – November 6, 2026”

      From the company's release
      The share repurchases are a part of the share buyback program of up to SEK 15,000,000,000 which Ericsson announced on April 16, 2026, and which runs between April 23, 2026, and March 31, 2027, at the latest.

    On GestorLens

    • 393 13F filers
    GestorLens profile
  • BellRing Brands

    BRBR
    • 13:04 ET5%+ stakesSEC Schedule 13G

      New passive 5%+ stake

      the Goldman Sachs Group and 1 related filer reported a stake: 6.7% (7,765,822 shares) (passive, 13G) as of September 30, 2026.

      Filed by: GOLDMAN SACHS GROUP INC

    On GestorLens

    • 4 concentrated managers (-3 this quarter)
    • 364 13F filers
    GestorLens profile
  • West Fraser Timber

    WFG
    • 12:58 ET5%+ stakesSEC Schedule 13D/A

      Change in a 5%+ stake with activist intent

      Banasino Investments S.a r.l. and 6 related filers updated their stake: 11% (8,356,494 shares) (active, 13D) as of November 5, 2026.

      Filed by: Banasino Investments S.a r.l.

    On GestorLens

    • 7 concentrated managers
    • 166 13F filers
    GestorLens profile
  • Mueller Industries

    MLI
    • 12:37 ETDividends and buybacksSEC 8-K 5.02

      Dividend announcement

      Quarterly dividend of $0.175 per share, payable December 18, 2026 to shareholders of record on December 4, 2026.

      Company headline: “Mueller Industries, Inc. Declares Cash Dividend for Fourth…”

      Also: Other events

      From the filing
      On November 6, 2026, the Registrant issued a press release announcing that its Board has declared a regular quarterly cash dividend of 17.5 cents per share on its common stock. The dividend will be paid December 18, 2026 to shareholders of record on December 4, 2026.

    On GestorLens

    • 4 concentrated managers
    • 743 13F filers
    GestorLens profile
  • Flutter Entertainment

    FLUT
    • 12:16 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: James Philip Bishop may sell up to 13,125 shares (~$1.1 million) on or about November 9, 2026.

    On GestorLens

    • 9 concentrated managers (-8 this quarter)
    • 405 13F filers
    • 2 insiders bought in 180 days ($299,587)
    GestorLens profile
  • Circle Internet Group

    CRCL
    • 12:11 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Nikhil Chandhok (officer) may sell up to 26,668 shares (~$1.8 million) on or about November 9, 2026.

    On GestorLens

    • 8 concentrated managers (+1 this quarter)
    • 568 13F filers
    GestorLens profile
  • Charles Schwab

    SCHW
    • 12:09 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Charles R. Schwab (officer, director) may sell up to 70,750 shares (~$6.6 million) on or about November 9, 2026.

    On GestorLens

    • 47 concentrated managers
    • 2,328 13F filers
    • 1 insider bought in 180 days ($1.8M)

    Well-known investors: Giverny Capital, Viking Global, Markel Group

    GestorLens profile
  • RPM International

    RPM
    • 11:28 ETEarningsSEC 8-K 7.01

      Regulation FD disclosure

      Company headline: “Achieve our best results yet. N O V E M B E R 9 , 2 0 2 6”

      From the company's release
      RPM At a Glance 50% / 50% Split between coatings & construction chemicals 65% / 35% Repair & Maintenance vs. OEM / New Construction DIVIDEND RECORD Q U I C K FA C T S MANUFACTURING FACILITIES IN 22 COUNTRIES FOUNDED: 1947 HEADQUARTERS: Medina, OH A world leader in 53 NYSE consecutive years specialty coatings, STOCK LISTING: (Symbol: RPM) of dividend increases sealants…

    On GestorLens

    • 2 concentrated managers (+1 this quarter)
    • 799 13F filers
    GestorLens profile
  • Ferrari

    RACE
    • 11:12 ETDividends and buybacksSEC 6-K

      Foreign issuer report

      Company announcement.

      Company headline: “Ferrari N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM”

      From the company's release
      Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 250 million share buyback program announced on September 1, 2026, as the third tranche of the multi-year share buyback program of approximately Euro 3.5 billion expected to be executed by 2030 in line with the disclosure made during the 2025 Capital Markets Day (the “Third Tranche”)…

    On GestorLens

    • 18 concentrated managers (+2 this quarter)
    • 718 13F filers
    • 1 13D filings in the last year

    Well-known investors: Viking Global

    GestorLens profile
  • TTM Technologies

    TTMI
    • 10:52 ETInsider buyingSEC Form 4 (P)

      Open-market purchase by an insider

      Philip G Franklin (director) bought 5,000 shares for $309,600 (avg. $61.92).

    On GestorLens

    • 16 concentrated managers (+6 this quarter)
    • 645 13F filers
    • 3 insiders bought in 180 days ($3.6M)

    Well-known investors: Lone Pine, Dan Loeb

    GestorLens profile
  • Airbnb

    ABNB
    • 10:49 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Nathan Blecharczyk (officer, director) may sell up to 13,625 shares (~$2.6 million) on or about November 9, 2026.

    On GestorLens

    • 26 concentrated managers (+1 this quarter)
    • 1,314 13F filers

    Well-known investors: Akre Capital, Markel Group

    GestorLens profile
  • GRAB Holdings

    GRAB2 filings
    • 10:41 ETOtherSEC 6-K

      Foreign issuer report

      Company announcement.

      Company headline: “SoftBank Group, Grab and PETROS Plan to Invest US$1 Billion to Develop AI Infrastructure in Sarawak”

      From the company's release
      SoftBank Group Corp. (TSE: 9984, “SBG”, and together with its subsidiaries and affiliates, the “SoftBank Group”), Grab Holdings Limited (NASDAQ: GRAB) (“Grab”) and Petroleum Sarawak Berhad (“PETROS”) today announced the signing of a Joint Development Agreement (JDA) in connection with plans for US$1 billion (approximately RM4.07 billion) in initial combined seed capital to develop AI infrastructure in Sarawak.
    • 10:38 ETOtherSEC 6-K

      Foreign issuer report

      Company announcement.

      Company headline: “SoftBank Group, Grab and PETROS Plan to Invest US$1 Billion to Develop AI Infrastructure in Sarawak”

      From the company's release
      Building on the Framework Agreement signed by the three parties in Kuching, Malaysia, on October 8, 2026, the JDA marks the next phase of the partnership to advance plans to develop AI infrastructure in Sarawak by combining SoftBank Group's global AI and technology capabilities, Grab's digital and AI expertise, and PETROS' local energy and infrastructure development experience.

    On GestorLens

    • 13 concentrated managers (-1 this quarter)
    • 487 13F filers
    • 2 insiders bought in 180 days ($30.8M)
    • 1 13D filings in the last year
    GestorLens profile
  • Jackson Financial

    JXN
    • 10:36 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Laura Louene Prieskorn may sell up to 86,595 shares (~$11.6 million, 0.13% of shares outstanding) on or about November 9, 2026.

    On GestorLens

    • 1 concentrated managers
    • 506 13F filers
    GestorLens profile
  • Equifax

    EFX
    • 10:29 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Jamil Farshchi (officer) may sell up to 15,110 shares (~$2.9 million) on or about November 9, 2026.

    On GestorLens

    • 26 concentrated managers
    • 839 13F filers

    Well-known investors: Markel Group

    GestorLens profile
  • Cincinnati Financial

    CINF
    • 10:13 ETOtherSEC 8-K 7.01

      Regulation FD disclosure

      From the filing
      On November 9, 2026, Cincinnati Financial Corporation posted presentation slides in PDF format on investors.cinfin.com that will be used in investor presentations beginning November 10, 2026.

    On GestorLens

    • 3 concentrated managers
    • 957 13F filers
    • 1 insider bought in 180 days ($171,640)
    GestorLens profile
  • Quest Diagnostics

    DGX
    • 10:11 ETPlanned insider salesSEC Form 144

      Notice of proposed sale (Form 144)

      Notice of proposed sale: Patrick Plewman (officer) may sell up to 11,717 shares (~$3.0 million) on or about November 9, 2026.

    On GestorLens

    • 14 concentrated managers (+2 this quarter)
    • 1,110 13F filers
    GestorLens profile
  • Fox

    FOXA
    • 09:08 ETOtherSEC 8-K/A 8.01

      Other events

      Company headline: “All references to the “Company” or “FOX” refer to the combined company post completion of the acquisition of Roku, Inc. by Fox”

      From the company's release
      All references to the “Company” or “FOX” refer to the combined company post completion of the acquisition of Roku, Inc. by Fox Corporation for a combination of cash and FOX Class A Common Stock (the “Roku Transaction”).

    On GestorLens

    • 7 concentrated managers (+2 this quarter)
    • 748 13F filers
    • 1 insider bought in 180 days ($10.3M)

    Well-known investors: Stanley Druckenmiller

    GestorLens profile
  • Somnigroup International

    SGI2 filings
    • 09:07 ETOtherSEC 8-K 7.01

      Regulation FD disclosure

      Company headline: “High-level strategic direction • Corporate governance • Capital allocation Tactical go-to-market strategy • Operational excellence • Passionate customer service 3 SOMNIGROUP’S STRUCTURE”

      From the company's release
      9 Retail stores include wholly owned and joint venture locations SOMNIGROUP’S GLOBAL E-COMMERCE RETAIL FOOTPRINT Europe Tempur Sealy (20) Dreams (2) North America Tempur Sealy (4) Mattress Firm (1) AsiaPac Tempur (10) Joint Venture (12) With ~20%1 of industry transactions occurring online…
    • 06:37 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 (ended September 30, 2026) results: revenue of $2.4 billion.

      Company headline: “SOMNIGROUP INTERNATIONAL INC. REPORTS RECORD THIRD QUARTER 2026 RESULTS”

      Also: Other events

      From the company's release
      - Third Quarter Net Sales increased 11% to $2.4 Billion

    On GestorLens

    • 26 concentrated managers (+1 this quarter)
    • 540 13F filers
    • 1 insider bought in 180 days ($1.9M)

    Well-known investors: Dan Loeb, Soros Fund

    GestorLens profile
  • Veradermics

    MANE
    • 09:04 ETOtherSEC 8-K 8.01

      Other events

      Company headline: “Veradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study '302' Data in Male Pattern Hair Loss”

      Also: Regulation FD disclosure

      From the company's release
      Veradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study '302' Data in Male Pattern Hair Loss VDPHL01, a novel orally-administered extended-release minoxidil formulation…

    On GestorLens

    • 5 concentrated managers
    • 164 13F filers
    • 4 13D filings in the last year

    Well-known investors: Viking Global

    GestorLens profile
  • Century Communities

    CCS
    • 09:00 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      James Francescon appointed President, effective January 1, 2027.

      Company headline: “For information, contact: Michelle Cahill”

      Also: Regulation FD disclosure

      From the filing
      On November 4, 2026, in furtherance of its succession planning efforts, the Board of Directors (the “Board”) of Century Communities, Inc. (the “Company”) elected James Francescon as President of the Company, effective as of January 1, 2027, succeeding Robert J. Francescon in that role, who will continue to serve as the Company’s Chief Executive Officer.

    On GestorLens

    • 3 concentrated managers
    • 265 13F filers
    GestorLens profile
  • SM Energy

    SM
    • 08:55 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      From the filing
      On November 9, 2026, SM Energy Company (the “Company”) announced the appointment of George Green as Senior Vice President – Chief Legal Officer and Corporate Secretary, effective November 9, 2026.

    On GestorLens

    • 5 concentrated managers (-1 this quarter)
    • 497 13F filers
    GestorLens profile
  • Coursera

    COUR
    • 08:54 ETDeals and acquisitionsSEC 8-K 1.01

      Entry into a material agreement

      Company headline: “Coursera Adopts Limited-Duration Stockholder Rights Plan”

      Also: Change in shareholders' rights; Amendments to bylaws or fiscal year; Regulation FD disclosure

    On GestorLens

    • 3 concentrated managers (-1 this quarter)
    • 251 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Axogen

    AXGN
    • 08:52 ETOtherSEC 8-K 7.01

      Regulation FD disclosure

      Company headline: “Prostate Nerve Reconstruction Investor Event November 9, 2026”

      From the company's release
      To restore health and improve quality of life by making restoration of peripheral nerve function an expected standard of care. Our Mission 4 Our Decision to Move Forward with a Prostate Market Launch Market Opportunity 5 Surgical Technique with Avance ® (acellular nerve allograft-arwx) Clinical ImpactClinical Need Is the need real and meaningful to patients?

    On GestorLens

    • 7 concentrated managers
    • 255 13F filers
    GestorLens profile
  • Warner Music Group

    WMG
    • 08:51 ETDividends and buybacksSEC 8-K 8.01

      Dividend announcement

      Quarterly dividend of $0.20 per share, payable December 1, 2026 to shareholders of record on November 20, 2026.

      Company headline: “Warner Music Group Corp. Announces Quarterly Cash Dividend”

      From the filing
      The dividend is payable on December 1, 2026, to stockholders of record as of the close of business on November 20, 2026.

    On GestorLens

    • 5 concentrated managers (+1 this quarter)
    • 337 13F filers
    GestorLens profile
  • Bitmine Immersion Technologies

    BMNR
    • 08:45 ETOtherSEC 8-K 7.01

      Regulation FD disclosure

      Company headline: “Immersion Technologies (BMNR) Announces ETH Holdings Reach 6.07 Million Tokens, and Total Crypto and Total Cash & Marketable Securities”

      From the company's release
      Bitmine has 5,227,037 staked ETH, representing $11.7 billion at $2,234 per ETH. MAVAN (Made in America VAlidator Network) is a premier Ethereum staking destination for BMNR and institutional investors

    On GestorLens

    • 443 13F filers
    GestorLens profile
  • Faeth Therapeutics

    FTH2 filings
    • 08:45 ETOtherSEC 8-K 8.01

      Other events

      Company headline: “FAETH THERAPEUTICS PIKTOR Phase 2”

      From the company's release
      We believe PIKTOR is the first oral multinode PAM inhibitor to show potentially durable activity in endometrial cancer 2 Encouraging preliminary PFS in post-I/O, post-platinum setting Confirmed ORR of 33%1, DCR of 83%, with KM estimated mPFS of 7.4 months Confirmed ORR of 44%, DCR of 81% among patients with PIK3CA mutation 3 Low discontinuation and low PAM-class toxicity Low rates of PAM-related toxicities…
    • 07:19 ETEarningsSEC 8-K 7.01

      Regulation FD disclosure

      Company headline: “Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer”

      From the company's release
      The Phase 2 trial is ongoing, and the topline data include 42 patients with endometrioid endometrial cancer who had a median of 2 prior lines of therapy (range 1-4 lines).

    On GestorLens

    • 9 concentrated managers (+5 this quarter)
    • 45 13F filers
    • 2 insiders bought in 180 days ($2.5M)
    GestorLens profile
  • Golar LNG

    GLNG
    • 08:40 ET5%+ stakesSEC Schedule 13G

      New passive 5%+ stake

      Luxor Capital Group and 9 related filers reported a stake: 7% (7,132,611 shares) (passive, 13G) as of November 2, 2026.

      Filed by: Luxor Capital Group, LP

    On GestorLens

    • 10 concentrated managers
    • 314 13F filers
    GestorLens profile
  • Innovative Industrial Properties

    IIPR
    • 08:39 ETOtherSEC 8-K 8.01

      Other events

      From the filing
      On November 9, 2026, Innovative Industrial Properties, Inc. (the “Company”) and IIP Operating Partnership, LP entered into amendments (collectively, the “Amendments”) to each of the Company's existing equity distribution agreements with BTIG, LLC, Piper Sandler & Co. and Roth Capital Partners, LLC (or their respective affiliates or agents), dated May 24, 2024, Stifel, Nicolaus & Company…

    On GestorLens

    • 329 13F filers
    • 1 insider bought in 180 days ($29,938)
    GestorLens profile
  • Ss&c Technologies Holdings

    SSNC
    • 08:39 ETDeals and acquisitionsSEC 8-K 1.01

      Entry into a material agreement

      Also: New direct financial obligation; Unregistered sale of equity; Other events

      From the filing
      On November 6, 2026, SS&C Technologies Holdings, Inc. (the “Company”) completed its previously announced upsized private offering (the “Offering”) of $1,200,000,000 aggregate principal amount of 2.75% Convertible Senior Notes due 2031 (the “Notes”), including $150,000,000 aggregate principal amount of Notes pursuant to the exercise in full of the initial purchasers’ option to purchase additional Notes.

    On GestorLens

    • 15 concentrated managers (+2 this quarter)
    • 729 13F filers
    GestorLens profile
  • Sonoco Products

    SON
    • 08:38 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      R. Howard Coker to retire as Director, President and Chief Executive Officer, effective December 31, 2026.

      Company headline: “November 9, 2026 Contact: Roger Schrum”

      Also: Regulation FD disclosure

      From the filing
      On November 6, 2026, R. Howard Coker, Director, President and Chief Executive Officer of Sonoco Products Company (the “Company”), notified the Company of his decision to retire as Director, President and Chief Executive Officer, effective December 31, 2026 (the “Effective Date”).

    On GestorLens

    • 3 concentrated managers (+2 this quarter)
    • 509 13F filers
    • 1 insider bought in 180 days ($249,446)
    GestorLens profile
  • Fervo Energy

    FRVO
    • 08:37 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 (ended September 30, 2026) results: loss per share of $0.07.

      Company headline: “Fervo Energy Reports Third Quarter 2026 Results”

      From the company's release
      Reported Q3 2026 net income of $11.7 million and net loss attributable to common stockholders of $20.8 million, or $(0.07) per share.

    On GestorLens

    • 4 concentrated managers (+4 this quarter)
    • 183 13F filers

    Well-known investors: Soros Fund, Viking Global

    GestorLens profile
  • Newell Brands

    NWL
    • 08:35 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      Company headline: “Newell Brands Elects William “Bill” Newlands to Board of Directors”

      From the filing
      On November 4, 2026, the Board of Directors (the “Board”) of Newell Brands Inc. (the “Company”) voted to increase the size of the Board from eight members to nine and to elect William Newlands to the Board, effective January 1, 2027.

    On GestorLens

    • 3 concentrated managers (+1 this quarter)
    • 425 13F filers
    GestorLens profile
  • Vir Biotechnology

    VIR
    • 08:31 ETOtherSEC 8-K 8.01

      Other events

      Also: Regulation FD disclosure

      From the filing
      Certain data from the ongoing Phase 3 ECLIPSE 1 clinical trial, including the ECLIPSE 1 TLR, were presented in an oral session at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, in Denver, Colorado on November 8, 2026.

    On GestorLens

    • 5 concentrated managers (+1 this quarter)
    • 235 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Neurogene

    NGNE
    • 08:19 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “Neurogene Reports Third Quarter 2026 Financial Results and Highlights Recent Updates”

      From the company's release
      Anticipate reporting topline data from the Embolden™ registrational trial in the second half of 2027 oAs previously announced, the Embolden trial was overenrolled due to strong demand from the Rett syndrome community.

    On GestorLens

    • 9 concentrated managers (+1 this quarter)
    • 111 13F filers
    GestorLens profile
  • Heron Therapeutics

    HRTX2 filings
    • 08:15 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: revenue of $35.3 million.

      Company headline: “Heron Therapeutics Announces Third Quarter 2026 Financial Results”

      From the company's release
      Heron generated total net revenue of $35.3 million in Q3 2026, compared to $38.2 million in Q3 2025 and $37.7 million in Q2 2026. Heron ended the third quarter with $23.4 million in cash, cash equivalents and short-term investments.
    • 07:40 ETDeals and acquisitionsSEC 8-K 1.01

      Entry into a material agreement

      Also: Change in shareholders' rights; Regulation FD disclosure

      From the filing
      On November 8, 2026, Heron Therapeutics, Inc., a Delaware corporation (the “Company”), and CorMedix Inc., a Delaware corporation (the “Buyer”), entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company has agreed to sell substantially all of its assets to the Buyer, other than certain excluded assets…

    On GestorLens

    • 4 concentrated managers
    • 162 13F filers
    GestorLens profile
  • Mereo Biopharma Group

    MREO
    • 08:10 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “Mereo BioPharma Reports Third Quarter 2026 Financial Results”

      From the company's release
      “During the third quarter, we have made meaningful progress on our two core programs, setrusumab and alvelestat. These developments have the potential to set the stage for a transformational 2027 for Mereo, our shareholders and the patients we aim to serve,” said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma.

    On GestorLens

    • 3 concentrated managers
    • 57 13F filers
    GestorLens profile
  • ADC Therapeutics

    ADCT
    • 08:06 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 (ended September 30, 2026) results.

      Company headline: “ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates”

      From the company's release
      Strategic financial restructuring strengthens balance sheet and supports continued investment in ZYNLONTA. In October 2026, the Company announced a comprehensive strategic financial restructuring that included an $86.6 million private investment in public equity (PIPE) financing with participation from new investor Bain Capital Life Sciences and existing investors Redmile, TCGX, and Nantahala Capital.

    On GestorLens

    • 5 concentrated managers (+1 this quarter)
    • 113 13F filers
    GestorLens profile
  • LKQ

    LKQ
    • 08:05 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      Company headline: “Salvatore Abbate to Assume Role of LKQ President and CEO on November 9, 2026”

    On GestorLens

    • 12 concentrated managers (-1 this quarter)
    • 535 13F filers
    • 3 insiders bought in 180 days ($792,615)
    GestorLens profile
  • Evolv Technologies Holdings

    EVLV
    • 08:03 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      Jason Blessing joins the board, effective November 6, 2026.

      Company headline: “Evolv Technology Announces the Appointment of Jason Blessing as a New Independent Director”

      Also: Regulation FD disclosure

      From the filing
      On November 6, 2026, the Board of Directors (the “Board”) of Evolv Technologies Holdings, Inc. (the “Company”) appointed Jason Blessing, age 55, to the Board, effective November 6, 2026, to serve as a Class III director until the Company’s 2027 annual meeting of stockholders.

    On GestorLens

    • 3 concentrated managers (-1 this quarter)
    • 262 13F filers
    • 3 insiders bought in 180 days ($296,479)
    GestorLens profile
  • RB Global

    RBA
    • 08:02 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Results for the quarter ended September 30, 2026: revenue of $1.3 billion.

      Company headline: “RB Global reports third quarter 2026 results”

      Also: Other events

      From the company's release
      Revenue increased 17% year over year to $1.3 billion.

    On GestorLens

    • 9 concentrated managers
    • 562 13F filers
    • 2 insiders bought in 180 days ($184,781)
    GestorLens profile
  • CNH Industrial

    CNH2 filings
    • 08:02 ETDeals and acquisitionsSEC 8-K 1.01

      Entry into a material agreement

      Also: Regulation FD disclosure

      From the filing
      On November 9, 2026, CNH Industrial N.V. (“CNH” or the “Company”) and CNH Industrial America LLC, a Delaware limited liability company and a wholly owned subsidiary of the Company (the “U.S. Seller” and, together with the Company, the “Sellers”), entered into a Transaction Agreement (the “Transaction Agreement”) with Kobelco Construction Machinery Co., Ltd., a Japanese corporation (the “Purchaser”)…
    • 06:37 ETEarningsSEC 8-K 7.01

      Regulation FD disclosure

      Company headline: “CNH Industrial N.V. Reports Third Quarter 2026 Results”

      From the company's release
      Consolidated revenues for the third quarter of 2026 were $4.4 billion, approximately flat year over year Reported Net income was $35 million, including a $156 million non-cash charge to establish a valuation allowance against deferred tax assets; Adjusted Net income(1) was $205 million…

    On GestorLens

    • 9 concentrated managers
    • 522 13F filers

    Well-known investors: David Einhorn

    GestorLens profile
  • Turning Point Brands

    TPB
    • 08:01 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: revenue of $151.1 million; EPS of $0.19 (adjusted: $0.41).

      Company headline: “Turning Point Brands Announces Third Quarter 2026 Results”

      From the company's release
      Total Consolidated Net Sales increased 27.0% to $151.1 million o Stoker's segment Net Sales increased 52.0% o Zig-Zag segment Net Sales decreased 15.5%

    On GestorLens

    • 6 concentrated managers
    • 229 13F filers
    GestorLens profile
  • Argenx

    ARGX2 filings
    • 08:01 ETOtherSEC 6-K

      Foreign issuer report

      Company announcement.

      Company headline: “Phase 3 ALKIVIA Data at ACR Convergence 2026”

      From the company's release
      Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced that data from the Phase 3 ALKIVIA study demonstrating rapid and sustained improvement with VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in patients with autoimmune myositis will be featured in a late-breaking oral presentation (#LB24) at the American College of Rheumatology (ACR)…
    • 06:01 ETOtherSEC 6-K

      Foreign issuer report

      Company announcement.

      Company headline: “Argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities”

      From the company's release
      Amsterdam, the Netherlands, November 9, 2026, 07:00 CET – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced a definitive agreement to acquire Unnatural Products, Inc. (UNP), adding a macrocyclic peptide discovery engine to its immunology innovation capabilities. argenx, which already holds a minority stake in UNP…

    On GestorLens

    • 11 concentrated managers
    • 510 13F filers
    GestorLens profile
  • Orthofix Medical

    OFIX
    • 08:01 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: revenue of $207.9 million.

      Company headline: “Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance”

      Also: Regulation FD disclosure

      From the company's release
      Total reported net sales of $207.9 million, representing an increase of 1% on a reported basis and 2% on a pro forma constant currency basis compared with the prior year period.

    On GestorLens

    • 4 concentrated managers
    • 140 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Compass Therapeutics

    CMPX
    • 08:00 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update”

      From the company's release
      As previously reported, the study met its primary endpoint, with tovecimig plus paclitaxel demonstrating a statistically significant improvement in ORR of 18.0% vs. 5.3% with paclitaxel alone (p=0.0228).

    On GestorLens

    • 5 concentrated managers (-6 this quarter)
    • 215 13F filers
    • 1 insider bought in 180 days ($21,250)
    GestorLens profile
  • Profound Medical

    PROF
    • 08:00 ETOtherSEC 8-K 7.01

      Regulation FD disclosure

      Company headline: “Profound Medical to Participate in the Stifel 2026 Healthcare Conference”

      From the company's release
      Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced that its President, Richard Fabian, will present at the Stifel 2026 Healthcare Conference on Thursday, November 12, 2026 at 8:40 a.m. Eastern Time in NYC.

    On GestorLens

    • 3 concentrated managers
    • 55 13F filers
    GestorLens profile
  • CVR Energy

    CVI
    • 08:00 ETOtherSEC 8-K 7.01

      Regulation FD disclosure

      Company headline: “CON CONF FI IDEN DENT TI IA AL L Exhibit 99.1 PRELIMINARY DRAFT Project”

      From the company's release
      Target EBITDA for the twelve months ended September 30, 2026 calculated as income (loss) before income taxes plus depreciation and amortization per the combined carve-out financial statements of the St. Paul Park and Mandan refining business.

    On GestorLens

    • 2 concentrated managers
    • 223 13F filers
    • 1 13D filings in the last year

    Well-known investors: Carl Icahn

    GestorLens profile
  • Strategy

    MSTR
    • 08:00 ETOtherSEC 8-K 8.01

      Other events

      Also: Regulation FD disclosure

    On GestorLens

    • 1 concentrated managers (-1 this quarter)
    • 855 13F filers
    GestorLens profile
  • CECO Environmental

    CECO
    • 07:54 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: revenue of $404.4 million; loss per share of $0.03 (adjusted: earnings of $0.60).

      Company headline: “CECO ENVIRONMENTAL REPORTS THIRD QUARTER 2026 RESULTS”

      From the company's release
      Revenue of $404.4 million, up 105 percent

    On GestorLens

    • 1 concentrated managers (+1 this quarter)
    • 347 13F filers
    • 1 insider bought in 180 days ($1.5M)
    • 1 13D filings in the last year
    GestorLens profile
  • Bicara Therapeutics

    BCAX
    • 07:52 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 (ended September 30, 2026) results.

      Company headline: “Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update”

      From the company's release
      Cash, Cash Equivalents and Marketable Securities: As of September 30, 2026, Bicara had cash, cash equivalents and marketable securities of $442.3 million, compared to $414.8 million in cash, cash equivalents and marketable securities as of December 31, 2025.

    On GestorLens

    • 5 concentrated managers
    • 172 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • RadNet

    RDNT
    • 07:50 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: revenue of $115.4 million; EPS of $0.05.

      Company headline: “RadNet Reports Third Quarter Financial Results with Record Quarterly”

      From the company's release
      Revenue increased $115.4 million (or 22.1%) and Adjusted EBITDA(1) increased $20.2 million (or 23.8%) as compared with the third quarter of 2025.

    On GestorLens

    • 6 concentrated managers
    • 326 13F filers

    Well-known investors: Soros Fund

    GestorLens profile
  • Matador Resources

    MTDR
    • 07:41 ETInsider buyingSEC Form 4 (P)

      Open-market purchase by an insider

      Joseph Wm Foran (Chairman and CEO) bought 5,000 shares for $256,800 (avg. $51.36).

    On GestorLens

    • 7 concentrated managers
    • 495 13F filers
    • 8 insiders bought in 180 days ($2.1M)
    GestorLens profile
  • Popular

    BPOP
    • 07:39 ETOtherSEC 8-K 8.01

      Other events

      From the filing
      On November 9, 2026, Popular, Inc. (the “Corporation”) filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (the “Form 10-Q”).

    On GestorLens

    • 3 concentrated managers (+1 this quarter)
    • 478 13F filers
    GestorLens profile
  • Immunitybio

    IBRX2 filings
    • 07:39 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 (ended September 30, 2026) results.

      From the company's release
      ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million Label Expansion and Global Progress •FDA Expanded Approval: On October 14, 2026…
    • 06:33 ETOtherSEC 8-K 7.01

      Regulation FD disclosure

      Company headline: “ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial”

      From the company's release
      The trial involved over 75 clinical trial sites with three largest enrolling sites at US Urology Partners, Dartmouth-Hitchcock, and University of California Los Angeles.

    On GestorLens

    • 3 concentrated managers
    • 404 13F filers
    • 2 13D filings in the last year
    GestorLens profile
  • Viridian Therapeutics

    VRDN
    • 07:33 ETEarningsSEC 8-K 8.01

      Earnings

      Other events.

      Company headline: “Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing”

      Also: Regulation FD disclosure

      From the company's release
      Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing - VRDN-008, a half-life extended FcRn inhibitor, demonstrated deep and sustained IgG reduction through 8 weeks after subcutaneous dosing in healthy volunteers, with 74% reduction at peak - - VRDN-008 demonstrated an extended half-life of 15–18 days…

    On GestorLens

    • 10 concentrated managers (-2 this quarter)
    • 216 13F filers
    • 1 insider bought in 180 days ($20M)
    • 1 13D filings in the last year
    GestorLens profile
  • The Goodyear Tire & Rubber

    GT
    • 07:32 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      Roger J. Wood appointed Interim Chief Executive Officer and President, effective November 8, 2026.

      Company headline: “GOODYEAR PROVIDES CORPORATE UPDATE”

      Also: Regulation FD disclosure

      From the filing
      Effective on November 8, 2026, The Goodyear Tire & Rubber Company (the “Company”) appointed Roger J. Wood to be the Company’s Interim Chief Executive Officer and President, replacing Mark W. Stewart.

    On GestorLens

    • 3 concentrated managers
    • 375 13F filers

    Well-known investors: David Tepper

    GestorLens profile
  • AN2 Therapeutics

    ANTX
    • 07:31 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights”

      From the company's release
      Advancing startup activities for a Phase 2 proof-of-concept study in chronic Chagas disease The Company is advancing AN2-502998 (formerly known as AN15368), an oral, boron-based small molecule CPSF3 inhibitor for the treatment of chronic Chagas disease, also known as American trypanosomiasis.

    On GestorLens

    • 5 concentrated managers (+1 this quarter)
    • 66 13F filers
    • 1 insider bought in 180 days ($11,602)
    GestorLens profile
  • Ocular Therapeutix

    OCUL2 filings
    • 07:28 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      Seung Suh resigns from the board, effective December 31, 2026.

      From the filing
      On November 6, 2026, Seung Suh Hong, Ph.D., notified the Company of his resignation from the Board, effective December 31, 2026.
    • 07:08 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: revenue of $12.9 million.

      Company headline: “Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights”

      From the company's release
      Total net revenue was $12.9 million for the third quarter of 2026, compared with $14.5 million for the comparable quarter of 2025.

    On GestorLens

    • 8 concentrated managers (-1 this quarter)
    • 260 13F filers
    GestorLens profile
  • Cullinan Therapeutics

    CGEM
    • 07:20 ETOtherSEC 8-K 8.01

      Other events

      Company headline: “Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026”

      Also: Regulation FD disclosure

      From the company's release
      Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026 Clinically meaningful improvement in disease activity among 8 of 9 evaluable patients…

    On GestorLens

    • 12 concentrated managers
    • 183 13F filers
    GestorLens profile
  • Roivant Sciences

    ROIV
    • 07:17 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Company headline: “Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update”

      From the company's release
      “This quarter has marked a major transition for Roivant. LISRAYA is now commercially available to patients and we are off to a strong start, with $31.0 million in net product revenue in the first 5 weeks of launch – reflecting strong early patient and prescriber demand,” said Matt Gline, CEO of Roivant.

    On GestorLens

    • 11 concentrated managers (-2 this quarter)
    • 500 13F filers

    Well-known investors: David Einhorn, Viking Global

    GestorLens profile
  • Powerfleet

    AIOT
    • 07:13 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Fiscal Q2 2027 results: revenue of $115.7 million.

      Company headline: “Powerfleet Reports Results for Second Quarter Fiscal 2027”

      Also: Regulation FD disclosure

      From the company's release
      revenue of $115.7 million, 4% sequential growth.

    On GestorLens

    • 5 concentrated managers
    • 181 13F filers
    GestorLens profile
  • Tango Therapeutics

    TNGX
    • 07:13 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 (ended September 30, 2026) results.

      Company headline: “Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights”

      From the company's release
      Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progression-free survival (PFS) rate in patients with 2L/3L pancreatic cancer…

    On GestorLens

    • 15 concentrated managers (+3 this quarter)
    • 246 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Brady

    BRC
    • 07:11 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      Company headline: “Brady Corporation Strengthens Board with Finance and Technology Leaders Scott J. Robinson and Kenneth J. Spangler”

      From the filing
      Mr. Robinson was Senior Vice President, Chief Financial Officer for Donaldson Filtration Solutions from 2015 until his retirement in 2024. There are no actual or proposed transactions between Mr. Robinson or any of his related persons and the Company that would require disclosure under Item 404 (a) of Regulation S-K in connection with his appointment as a director of the Company.

    On GestorLens

    • 2 concentrated managers (+1 this quarter)
    • 337 13F filers
    • 1 insider bought in 180 days ($1M)
    GestorLens profile
  • Akamai Technologies

    AKAM
    • 07:10 ETDeals and acquisitionsSEC 8-K 1.01

      Entry into a material agreement

      Company headline: “Akamai Announces Proposed Offering of Convertible Senior Notes”

      Also: New direct financial obligation; Other events

      From the filing
      On November 5, 2026, Akamai Technologies, Inc. (“Akamai”) entered into an Amendment No. 4 (the “Fourth Amendment”), by and among Akamai, the financial institutions identified therein as lenders and JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”), which amends that certain Credit Agreement (the “Credit Agreement”), dated November 22, 2022 (as amended on April 17, 2025, May 12, 2025, and May 18…

    On GestorLens

    • 10 concentrated managers (-7 this quarter)
    • 809 13F filers
    GestorLens profile
  • Immunovant

    IMVT
    • 07:09 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Results for the quarter ended September 30, 2026.

      Company headline: “Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026”

      From the company's release
      Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026 •IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following open-label lead-in) of the potentially registrational trial in patients with difficult-to-treat rheumatoid arthritis (D2T RA)

    On GestorLens

    • 9 concentrated managers (-2 this quarter)
    • 225 13F filers
    • 1 13D filings in the last year

    Well-known investors: David Einhorn

    GestorLens profile
  • Ceva

    CEVA
    • 07:07 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 (ended September 30, 2026) results: revenue of $29.1 million; loss per share of $0.08.

      Company headline: “Ceva, Inc. Announces Third Quarter 2026 Financial Results”

      From the company's release
      Total revenues of $29.1 million, up 2% YoY.

    On GestorLens

    • 5 concentrated managers
    • 209 13F filers
    GestorLens profile
  • Zura Bio

    ZURA
    • 07:07 ETOtherSEC 8-K 8.01

      Other events

      Company headline: “Zura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa”

      From the company's release
      Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that its Phase 2 TibuSHIELD study, which evaluated tibulizumab (ZB-106) in adults with moderate-to-severe hidradenitis suppurativa (HS)…

    On GestorLens

    • 8 concentrated managers (-1 this quarter)
    • 95 13F filers
    • 2 13D filings in the last year
    GestorLens profile
  • Affiliated Managers Group

    AMG
    • 07:06 ETDividends and buybacksSEC 8-K 2.02

      Dividend announcement

      Quarterly dividend of $0.01 per share, payable December 3, 2026 to shareholders of record on November 19, 2026.

      Company headline: “AMG Reports Financial and Operating Results for the Third Quarter and Nine Months Ended 2026”

      Also: Other events

      From the filing
      The press release announced that the Company's Board of Directors authorized and declared a quarterly dividend of $0.01 per share of common stock, payable December 3, 2026 to stockholders of record as of the close of business on November 19, 2026.

    On GestorLens

    • 8 concentrated managers (-1 this quarter)
    • 568 13F filers
    • 1 insider bought in 180 days ($228,660)
    GestorLens profile
  • Foghorn Therapeutics

    FHTX
    • 07:06 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Company headline: “Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update”

      Also: Regulation FD disclosure

      From the company's release
      Collaboration Revenue. Collaboration revenue was $83.5 million for the three months ended September 30, 2026, compared to $8.2 million for the three months ended September 30, 2025.

    On GestorLens

    • 5 concentrated managers (+1 this quarter)
    • 101 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Select Water Solutions

    WTTR
    • 07:05 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Results for the quarter ended September 30, 2026: revenue of $412 million.

      Company headline: “Ken Dennard / Natalie Hairston”

      From the company's release
      Select Water Solutions Announces Third Quarter 2026 Financial, Operational and Strategic Updates Generated third quarter 2026 consolidated revenue of $412 million, an increase of $90 million or 28% year-over-year, as compared to the third quarter of 2025 Produced net income of $23 million during the third quarter of 2026…

    On GestorLens

    • 3 concentrated managers
    • 266 13F filers
    GestorLens profile
  • Aura Biosciences

    AURA
    • 07:05 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 (ended September 30, 2026) results.

      Company headline: “Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights”

      Also: Other events

      From the company's release
      Enrollment is complete with 108 participants in the Phase 3 CoMpass trial of belzupacap sarotalocan (bel-sar) for the treatment of early choroidal melanoma, the most common primary tumor of the eye which carries an approximately 50% risk of advancing to metastatic disease.

    On GestorLens

    • 10 concentrated managers (+7 this quarter)
    • 146 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Editas Medicine

    EDIT
    • 07:04 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: loss per share of $0.15.

      Company headline: “Editas Medicine Announces Third Quarter 2026 Results and Business Updates”

      From the company's release
      For the three months ended September 30, 2026, net loss attributable to common stockholders was $23.4 million, or $0.15 per share, compared to net loss of $25.1 million, or $0.28 per share, for the same period in 2025.

    On GestorLens

    • 10 concentrated managers (+9 this quarter)
    • 216 13F filers
    GestorLens profile
  • TG Therapeutics

    TGTX
    • 07:04 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance”

      From the company's release
      TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance Raises full-year 2026 total global revenue guidance to approximately $1 billion, from approximately $950 million Raises full-year 2026 BRIUMVI U.S. net product revenue guidance to approximately $915–920 million, from $890–905 million Third-quarter 2026 total global revenue of approximately $260 million…

    On GestorLens

    • 3 concentrated managers
    • 432 13F filers
    GestorLens profile
  • NRG Energy

    NRG2 filings
    • 07:02 ETOtherSEC 8-K 7.01

      Regulation FD disclosure

      Company headline: “NRG Energy Announces $4 Billion Asset Sale”

      From the company's release
      Transaction monetizes select assets at an attractive valuation, supporting additional share repurchases, debt reduction, and flexibility to redeploy capital at higher returns.
    • 06:45 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 (ended September 30, 2026) results: adjusted EPS of $4.68.

      Company headline: “NRG Energy Reports Third Quarter 2026 Results, Reaffirms 2026 Financial Guidance, and Initiates 2027 Guidance”

      From the company's release
      The Company's non-GAAP metrics are Adjusted Net Income of $983 million, Adjusted EPS of $4.68, Adjusted EBITDA of $2,013 million, and Free Cash Flow before Growth Investments (FCFbG) of $1,242 million for the third quarter of 2026.

    On GestorLens

    • 13 concentrated managers (+2 this quarter)
    • 1,024 13F filers

    Well-known investors: David Tepper

    GestorLens profile
  • Praxis Precision Medicines

    PRAX
    • 07:02 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results”

      From the company's release
      As of September 30, 2026, Praxis had $1.3 billion in cash, cash equivalents and marketable securities, compared to $926.1 million in cash, cash equivalents and marketable securities as of December 31, 2025.

    On GestorLens

    • 11 concentrated managers (-2 this quarter)
    • 311 13F filers
    GestorLens profile
  • Precision Biosciences

    DTIL
    • 07:00 ETOtherSEC 8-K 8.01

      Other events

      From the filing
      As previously reported, on November 5, 2026, Precision BioSciences, Inc. (the “Company”) entered into an underwriting agreement relating to the issuance and sale by the Company of 10,235,077 shares of its common stock, $0.000005 par value per share (the “Common Stock”), at a price of $7.75 per share and, in lieu of Common Stock to certain investors…

    On GestorLens

    • 3 concentrated managers
    • 95 13F filers
    • 3 insiders bought in 180 days ($29,501)
    GestorLens profile
  • monday.com

    MNDY
    • 07:00 ETEarningsSEC 6-K

      Foreign issuer report

      Company announcement.

      Company headline: “monday.com Announces Third Quarter 2026 Results”

      From the company's release
      “Our third quarter results reflect disciplined execution on profitability,” said Eliran Glazer, monday.com CFO. “Revenue grew 19% year-over-year to $377.5 million, and we delivered record non-GAAP operating income and operating margin.

    On GestorLens

    • 5 concentrated managers (-2 this quarter)
    • 275 13F filers
    GestorLens profile
  • Ionis Pharmaceuticals

    IONS
    • 07:00 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 (ended September 30, 2026) results.

      Company headline: “Ionis reports third quarter 2026 financial results and highlights progress on key programs”

      From the company's release
      Ionis reports third quarter 2026 financial results and highlights progress on key programs – ZANVASTROTM (zilganersen) first approved medicine for Alexander disease; first independent launch underway from leading neurology pipeline – – TRYNGOLZA® (olezarsen) 2026 product sales guidance lowered as sHTG launch ramps more gradually than expected reflecting early dynamics of establishing a new treatment paradigm – –…

    On GestorLens

    • 15 concentrated managers (+1 this quarter)
    • 517 13F filers
    • 1 insider bought in 180 days ($1.1M)
    GestorLens profile
  • Joint Stock Company Kaspi.kz

    KSPI
    • 07:00 ETEarningsSEC 6-K

      Foreign issuer report

      Company announcement.

      Company headline: “Kaspi.kz 3Q & 9M 2026 Financial Results”

      From the company's release
      Joint Stock Company Kaspi.kz (“Kaspi.kz”) (Nasdaq:KSPI) today published its unaudited consolidated IFRS financial results for the quarter and nine months ended 30 September 2026 (“3Q and 9M 2026”).

    On GestorLens

    • 20 concentrated managers (+1 this quarter)
    • 205 13F filers
    GestorLens profile
  • Wise Group

    WSE
    • 06:55 ET5%+ stakesSEC Schedule 13G/A

      Change in a passive 5%+ stake

      Baillie Gifford updated its stake: 9.1% (92,932,028 shares) (passive, 13G) as of September 30, 2026.

      Filed by: BAILLIE GIFFORD & CO

    On GestorLens

    • 3 concentrated managers (+3 this quarter)
    • 214 13F filers
    GestorLens profile
  • Cenovus Energy

    CVE
    • 06:54 ETOtherSEC 6-K

      Foreign issuer report

      Company announcement.

      Company headline: “Cenovus Energy announces renewal of normal course issuer bid”

      From the company's release
      Cenovus Energy Inc. (TSX: CVE) (NYSE: CVE) announced today that the Toronto Stock Exchange (“TSX”) has approved the renewal of the company’s normal course issuer bid (“NCIB”) to purchase up to 126,482,982 common shares during the 12-month period commencing November 11, 2026, and ending November 10, 2027.

    On GestorLens

    • 10 concentrated managers (-2 this quarter)
    • 493 13F filers
    GestorLens profile
  • Constellation Energy

    CEG
    • 06:53 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “CONSTELLATION REPORTS THIRD QUARTER 2026 RESULTS”

      Also: Regulation FD disclosure

      From the company's release
      1 “Third quarter adjusted operating earnings were $5.06 per share, compared with $3.04 a year ago. This strong performance allowed us to raise the midpoint of our adjusted operating earnings guidance range for the second time this year,” said Shane Smith, executive vice president and chief financial officer of Constellation.

    On GestorLens

    • 24 concentrated managers (+1 this quarter)
    • 1,868 13F filers
    • 1 insider bought in 180 days ($417,930)

    Well-known investors: Coatue, Soros Fund

    GestorLens profile
  • KKR

    KKR
    • 06:51 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “KKR & Co. Inc. Reports Third Quarter 2026 Financial Results November 9, 2026”

      From the company's release
      Fund Investment Performance Private Equity Real Assets Infrastructure Portfolio Opportunistic Real Estate Portfolio Credit Alternative Credit Composite Traditional Private Equity Portfolio Leveraged Credit Composite 3Q'26 (2)% LTM Gross Return (2)% 7%0% 4%3% 9%4% 4%1% Note: Traditional private equity does not include core or growth.

    On GestorLens

    • 20 concentrated managers (-1 this quarter)
    • 1,284 13F filers

    Well-known investors: Akre Capital, ValueAct, Markel Group, Soros Fund

    GestorLens profile
  • Target Hospitality

    TH
    • 06:51 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Results for the quarter ended September 30, 2026: revenue of $129.1 million.

      Company headline: “Target Hospitality Announces Third Quarter 2026 Results Reflecting Execution at Scale and Building Momentum on Continued Strategic Transformation”

      From the company's release
      Revenue was $129.1 million for the three months ended September 30, 2026, compared to $99.4 million for the same period in 2025, a 30% increase.

    On GestorLens

    • 3 concentrated managers (+2 this quarter)
    • 171 13F filers
    • 2 insiders bought in 180 days ($375,158)
    • 1 13D filings in the last year
    GestorLens profile
  • Ferguson Enterprises

    FERG
    • 06:50 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Company headline: “Ferguson Reports Third Quarter Ended September 30, 2026”

      From the company's release
      November 9, 2026, Newport News, VA— Ferguson Enterprises Inc. (NYSE: FERG). Kevin Murphy, Ferguson CEO, commented, “Our expert associates delivered strong third quarter results, with non-residential sales up 15% and residential growth of 6%.

    On GestorLens

    • 34 concentrated managers
    • 949 13F filers

    Well-known investors: Seth Klarman, Markel Group, Giverny Capital

    GestorLens profile
  • Abeona Therapeutics

    ABEO2 filings
    • 06:35 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results.

      Company headline: “Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress”

      Also: Regulation FD disclosure

      From the company's release
      Abeona acquired APT-1011, now ABO-801, from Ellodi Pharmaceuticals and announced a $30 million PIPE financing. In a separate press release issued today, Abeona announced the acquisition of ABO-801, a Phase 3-ready, once-daily oral disintegrating tablet formulation of fluticasone propionate in development for EoE.
    • 06:30 ETDeals and acquisitionsSEC 8-K 2.01

      Completed acquisition or sale of assets

      Also: Entry into a material agreement; Unregistered sale of equity; Regulation FD disclosure

    On GestorLens

    • 4 concentrated managers
    • 126 13F filers
    • 1 13D filings in the last year
    GestorLens profile
  • Kodiak Gas Services

    KGS
    • 06:32 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Results for the quarter ended September 30, 2026.

      Company headline: “Kodiak Gas Services Reports Third Quarter 2026 Financial Results, Increases Full Year 2026 Adjusted EBITDA and Discretionary Cash Flow Guidance”

      From the company's release
      Increased Adjusted EBITDA guidance to a range of $840 million to $860 million and discretionary cash flow guidance to a range of $580 million to $600 million •Reduced Power Infrastructure segment growth capital expenditures to reflect updated expectations for the timing of new equipment deliveries…

    On GestorLens

    • 8 concentrated managers (+4 this quarter)
    • 408 13F filers

    Well-known investors: Lone Pine

    GestorLens profile
  • SBA Communications

    SBAC
    • 06:30 ETDeals and acquisitionsSEC 8-K 1.01

      Entry into a material agreement

      Also: New direct financial obligation

      From the filing
      On November 6, 2026 (the “Closing Date”), SBA Communications Corporation (the “Company”) entered into a Term Loan Credit Agreement, dated as of November 6, 2026 (the “Term Loan Credit Agreement”), among the Company, as borrower, the several lenders from time to time party thereto, Wells Fargo Bank, National Association, as administrative agent, and Citibank, N.A., as syndication agent.

    On GestorLens

    • 12 concentrated managers (+1 this quarter)
    • 683 13F filers
    GestorLens profile
  • Taiwan Semiconductor Manufacturing

    TSM
    • 06:15 ETInsider buyingSEC Form 4 (P)

      Open-market purchase by an insider

      Michael R Splinter (director) bought 840 shares for $299,880 (avg. $357.00).

    On GestorLens

    • 179 concentrated managers (+16 this quarter)
    • 3,594 13F filers
    • 1 insider bought in 180 days ($16,618)

    Well-known investors: David Tepper, Tiger Global, Coatue, Stanley Druckenmiller and 4 more

    GestorLens profile
  • Charles River Laboratories International

    CRL
    • 06:13 ETOtherSEC 8-K 7.01

      Regulation FD disclosure

      Company headline: “LABORATORIES TO ACQUIRE FRONTAGE’S BIOANALYSIS AND DMPK BUSINESSES”

      From the company's release
      Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has entered into definitive agreements to acquire Frontage Holdings Corporation’s bioanalysis and DMPK operations in Exton, Pennsylvania for approximately $470 million in cash, subject to customary closing adjustments.

    On GestorLens

    • 5 concentrated managers
    • 569 13F filers
    GestorLens profile
  • KE Holdings

    BEKE
    • 06:13 ETOtherSEC 6-K

      Foreign issuer report

      Company announcement.

      Company headline: “Next Day Disclosure Return”

      From the company's release
      Section I must be completed by a listed issuer where there has been a change in its issued shares or treasury shares which is discloseable pursuant to rule 13.25A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Exchange”) (the “Main Board Rules”) or rule 17.27A of the Rules Governing the Listing of Securities on GEM of the Exchange (the “GEM Rules”).

    On GestorLens

    • 4 concentrated managers (+1 this quarter)
    • 204 13F filers
    • 3 13D filings in the last year
    GestorLens profile
  • Berkshire Hathaway

    BRK/B
    • 06:10 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      From the company's release
      In the table above, investment gains (losses) in each period predominantly relate to our investments in equity securities. Generally Accepted Accounting Principles (“GAAP”) require that we include the changes in unrealized gains (losses) of our equity security investments as a component of investment gains (losses) in our earnings statements.

    On GestorLens

    • 148 concentrated managers (-1 this quarter)
    • 4,942 13F filers
    • 1 insider bought in 180 days ($250,072)

    Well-known investors: Gates Foundation Trust, Semper Augustus, Li Lu, Markel Group and 4 more

    GestorLens profile
  • Hawaiian Electric Industries

    HE
    • 06:07 ETOtherSEC 8-K 7.01

      Regulation FD disclosure

      Company headline: “HEI 2026 EEI Financial Conference Investor Meetings”

      From the company's release
      Planned Resilience and New Generation Support Significant Grid Investment Opportunities 30 C o m pe tit iv e p ro cu re m en ts WMP im plem en ta tio n Foste rdis tr ib u te d gen er at io n In v estin m odern, resilientgrid Holistic planning to deliver safety, reliability, resilience…

    On GestorLens

    • 2 concentrated managers
    • 338 13F filers
    GestorLens profile
  • Cabaletta Bio

    CABA
    • 06:04 ETOtherSEC 8-K 8.01

      Other events

      Company headline: “Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases”

      Also: Regulation FD disclosure

      From the company's release
      “In three different autoimmune diseases where patients are at risk of severe disability, end-organ damage, and increased risk of death despite current therapies, a single weight-based dose of rese-cel delivered immunomodulator-free clinical improvements that were durable through at least one year with a favorable benefit-risk profile,” said David J. Chang, M.D., Chief Medical Officer of Cabaletta.

    On GestorLens

    • 3 concentrated managers
    • 139 13F filers
    GestorLens profile
  • Vistance Networks

    VISN
    • 06:04 ETLeadership changesSEC 8-K 5.02

      Departure or appointment of directors or officers

      Chuck Treadway steps down as President and Chief Executive Officer.

      Company headline: “Vistance Networks Announces CEO Succession Plan”

      From the filing
      On November 5, 2026, Vistance Networks, Inc. (the “Company”) announced that Chuck Treadway will step down as President and Chief Executive Officer (“CEO”) of the Company and as a member of the Board of Directors of the Company on February 1, 2027.

    On GestorLens

    • 2 concentrated managers (-2 this quarter)
    • 353 13F filers
    • 1 insider bought in 180 days ($107,500)
    GestorLens profile
  • Corebridge Financial

    CRBG
    • 06:02 ETDeals and acquisitionsSEC 8-K 1.01

      Entry into a material agreement

      From the filing
      On November 6, 2026, Corebridge Financial, Inc. (the “Company”) entered into a Share Repurchase Agreement (the “Share Repurchase Agreement”) with Argon Holdco LLC.

    On GestorLens

    • 2 concentrated managers (-1 this quarter)
    • 449 13F filers
    • 1 13D filings in the last year

    Well-known investors: Soros Fund, Viking Global

    GestorLens profile
  • Hdfc Bank

    HDB
    • 06:02 ETOtherSEC 6-K

      Foreign issuer report

      Company announcement.

      Company headline: “Sub: Appointment of Mr. V. N. Srivatsan as the Chief Compliance Officer of the Bank”

      From the company's release
      Dear Sir, Sub: Appointment of Mr. V. N. Srivatsan as the Chief Compliance Officer of the Bank We refer to our intimation dated September 30, 2026, wherein it was informed that based on the recommendations of the Audit Committee and the Governance, Nomination and Remuneration Committee, the Board of Directors of the Bank at its meeting held on September 30, 2026…

    On GestorLens

    • 31 concentrated managers (+3 this quarter)
    • 555 13F filers
    GestorLens profile
  • FTAI Aviation

    FTAI
    • 06:01 ETDeals and acquisitionsSEC 8-K 1.01

      Entry into a material agreement

      From the filing
      On November 6, 2026, FTAI Aviation Investors LLC (the “Issuer”), a subsidiary of FTAI Aviation Ltd. (“FTAI Aviation” and, together with its consolidated subsidiaries, the “Company,” “we,” “us” or “our”), issued $1.0 billion aggregate principal amount of its 7.125% Senior Notes due 2034 (the “Notes”).

    On GestorLens

    • 8 concentrated managers
    • 685 13F filers
    • 1 insider bought in 180 days ($498,143)

    Well-known investors: Stanley Druckenmiller

    GestorLens profile
  • Dole

    DOLE
    • 06:01 ETEarningsSEC 8-K 2.02

      Results of operations and financial condition

      Q3 2026 results: revenue of $2.4 billion.

      Company headline: “Dole plc Reports Third Quarter 2026 Financial Results”

      Also: Regulation FD disclosure

      From the company's release
      Due to the higher cost environment, our expectations for the remainder of the year have moderated and we are now targeting full-year Adjusted EBITDA in the range of $380 million to $390 million for 2026.”

    On GestorLens

    • 4 concentrated managers
    • 209 13F filers
    • 2 13D filings in the last year
    GestorLens profile
  • Tower Semiconductor

    TSEM
    • 06:01 ET5%+ stakesSEC Schedule 13G

      New passive 5%+ stake

      Clal Insurance Enterprises Holdings reported a stake: 5.6% (6,331,544 shares) (passive, 13G) as of November 2, 2026.

      Filed by: Clal Insurance Enterprises Holdings Ltd

    On GestorLens

    • 8 concentrated managers (-3 this quarter)
    • 456 13F filers
    GestorLens profile

What each filing is

Form 8-K
The current report of a material event: the company has 4 business days to file it. Each item is a type of event; the label is the one the company chose.
Schedule 13D
Whoever crosses 5% of the shares intending to influence the company (board seats, a sale, a change of strategy) files a 13D within 5 business days. It is the typical activist filing. More in the glossary
Schedule 13G
The form filed by whoever crosses 5% of a company's shares as a passive investor, with no intent to influence it. Mostly filed by large asset managers and index funds. More in the glossary
Form 4
The form directors, officers and 10%+ shareholders use to report every purchase or sale of their own company's shares, within 2 business days. Only open-market purchases (code P) are shown here. More in the glossary
Form 144
The notice an insider or major shareholder files BEFORE selling restricted shares, when the sale exceeds 5,000 shares or $50,000 in three months. It states how many shares they plan to sell and from when: it does not confirm the sale happened (that comes later in a Form 4).

Everything comes from SEC EDGAR, the system where companies file their documents with the SEC.

Source: SEC EDGAR. Text is built with fixed rules from each filing, without artificial intelligence; quotes stay in their original language. Times are New York (ET), with your browser's time next to them.

Filings are grouped by the New York date and time at which the SEC received each document.

Not investment advice. A notice of proposed sale (Form 144) does not confirm that a sale took place.

Follow the investors you care about

Build your list and get what they report by email, if you turn it on. Free, no credit card.

Create free account